

Table des matières

1. Systematic Reviews and Meta-Analysis	1
1.1. Generic Acupuncture	1
1.1.1. Zheng 2026 (Vs. Sham)	1
1.1.2. Gan 2022 (in addition to usual care) ☆☆	1
1.1.3. Shi 2022 (vs. antispasmodics) ☆☆	2
1.1.4. Wei 2022	3
1.1.5. Yang 2022	4
1.1.6. Amsallem 2021 ☆	5
1.1.7. Wang 2021 ☆	5
1.1.8. Billing 2020 ☆	6
1.1.9. Dai 2020 ☆☆	7
1.1.10. Zheng 2019	7
1.1.11. Fu 2018	8
1.1.12. Chao 2014 ☆☆	8
1.1.13. Pei 2012 ☆☆	9
1.1.14. Manheimer 2012 ☆☆	9
1.1.15. Manheimer 2012 ☆☆	10
1.1.16. Zhao 2010 ☆☆	11
1.1.17. Shen 2009 Ø	12
1.1.18. Lim 2006 ☆	12
1.1.19. Hussain 2006 Ø	13
1.2. Special Acupuncture Techniques	14
1.2.1. Placebo response	14
1.2.1.1. Wang 2025	14
1.2.2. Comparison of Acupuncture techniques	14
1.2.2.1. Zhang 2026	14
1.2.2.2. Zhou 2026	15
1.2.3. Acupoint application	16
1.2.3.1. Wang 2025	16
1.2.4. Moxibustion	16
1.2.4.1. Dai 2022	17
1.2.4.2. Tang 2016 ☆	17
1.2.4.3. Park 2013 ☆	17
1.2.5. Association with Chinese Herbal Medicine	18
1.2.5.1. Yan 2019 ★	18
1.2.6. Liver Dispersing with Spleen Strengthening	19
1.2.6.1. Li 2016 ☆☆	19
1.3. Special Clinical Forms	19
1.3.1. Diarrhea-Predominant Irritable Bowel Syndrome	20
1.3.1.1. Jiang 2022	20
1.3.1.2. Guo 2020 ☆	20
1.3.1.3. Deng 2017 ☆☆	21
1.4. Special outcome	21
1.4.1. Quality of life	22
1.4.1.1. Zhou 2025	22
1.4.2. Anxiety and depression in irritable bowel syndrome	22
1.4.2.1. Fang 2025	22
1.4.2.2. Hou 2024	23
1.4.2.3. Wang 2024	24

1.4.2.4. Wang 2023	24
1.4.2.5. Li 2022	25
2. Overviews of Systematic Reviews	26
2.1. Ma 2024	26
2.2. Wu 2019 ☆	27
2.3. Zhang 2014 ☆	27
3. Methodological quality	28
3.1. Wang 2026	28
4. Clinical Practice Guidelines	29
4.1. European and North American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN and NASPGHAN) 2025 Ø	29
4.2. Joint Consensus from the Italian Societies 2023 Ø	29
4.3. Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS, Germany) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM, Germany) 2021 ⊕	29
4.4. Japanese Society of Gastroenterology (JSG, Japan) 2020 ⊕	30
4.5. Canadian Association of Gastroenterology 2019 Ø	30
4.6. British Society of Gastroenterology 2018 Ø	31
4.7. Sociedad Española de Patología Digestiva (SEPD, Espagne) 2016 Ø	31
4.8. World Gastroenterology Organisation (WGO) 2015 Ø	31
4.9. National Institute for Health and Care Excellence (NICE, UK) 2015 Ø	31
4.10. American College of Gastroenterology 2009 Ø	31
4.11. World Gastroenterology Organisation (WGO) 2009 Ø	32
5. Randomized Controlled Trials	32
5.1. Sources	32
5.2. List	32

Irritable Bowel Syndrome

Syndrome de l'intestin irritable : évaluation de l'acupuncture

Articles connexes: - [traitement par acupuncture](#) - [Acupuncture expérimentale](#) -

1. Systematic Reviews and Meta-Analysis

1.1. Generic Acupuncture

1.1.1. Zheng 2026 (Vs. Sham)

Zheng HZ, Zou HL, Chen BH, Li YJ, Wu WZ, Huang XB. Acupuncture versus sham non-acupoint acupuncture for irritable bowel syndrome: a systematic review and meta-analysis. Gastroenterology. 2026 Jul 7. <https://doi.org/10.1053/j.gastro.2026.06.017>

Background & aims	Irritable bowel syndrome (IBS) is a recurrent abdominal disease globally, with limited efficacious therapeutics. Acupuncture is increasingly gaining attention on IBS with inconsistent evidence. Therefore, this study aims to evaluate the specific effect of acupuncture versus sham non-acupoint controls on IBS.
Methods	International and Chinese databases were searched to identify eligible randomized controlled trials (RCTs). Primary outcomes included response rate, overall symptom severity, and quality of life (QOL). Data for dichotomous and continuous variables were extracted and pooled using risk ratios (RR), and standardized mean differences (SMD) or mean difference (MD) and 95% CIs.
Results	Twelve RCTs encompassing 1105 participants were included for systematic review and 11 RCTs for meta-analysis. Acupuncture demonstrated a significantly higher response rate for IBS compared to sham control (RR [95% CIs]: 1.61 [1.25, 2.07], I2=77%, 1004 participants). Acupuncture significantly improved the total symptom severity at the end of treatment as compared to sham acupuncture (SMD [95%CIs]: 0.79 [0.30, 1.28], I2 = 86%) and at follow-up (SMD [95%CIs]: 0.70 [0.22, 1.18], I2 = 83%). The significance was also noted for QOL at the end of treatment (SMD [95%CIs]: 0.36 [0.01, 0.71]). However, sensitivity analysis only confirmed the robustness regarding the response rate and symptom severity at the end of treatment.
Conclusions	We discovered acupuncture significantly improved IBS patients' response rate and overall symptom at the end of treatment, as compared to sham non-acupoint acupuncture. Due to the significant heterogeneity and low certainty of evidence, our work merits more confirmation by large-scale and high-quality trials.

1.1.2. Gan 2022 (in addition to usual care) ☆☆

Gan Y, Huang SL, Luo MQ, Chen M, Zheng H. Acupuncture in addition to usual care for patients with irritable bowel syndrome: a component network meta-analysis. Acupunct Med. 2022

Oct;40(5):403-414. <https://doi.org/10.1177/09645284221085280>

Objective	The efficacy of acupuncture alone in the treatment of irritable bowel syndrome (IBS) is controversial, but the benefit of acupuncture added to usual care has rarely been studied. We aimed to examine the benefit of acupuncture added to usual care through network meta-analysis (NMA).
Methods	PubMed, Embase, and the Cochrane Register of Controlled Trials (CENTRAL) were searched from their inception to 1 July 2021, without any language restriction. Randomized controlled trials (RCTs) testing the effect of acupuncture alone or acupuncture combined with usual care for IBS were included. The primary outcome was improvement of global IBS symptoms. Standard NMA was performed to compare differential combinations of acupuncture (including manual acupuncture (MA) and electroacupuncture (EA)), and component network meta-analysis (CNMA) was subsequently performed to determine whether acupuncture provided additional benefits to usual care. The effect size of an intervention was measured using relative ratio (RR).
Results	We included 25 RCTs (n = 3041 participants) after screening 582 retrieved articles. Five RCTs were classified as low risk of bias. The results of standard NMA showed that MA combined with usual care ranked the most effective (sham acupuncture as common comparator; RR = 1.96 (95% confidence interval (CI) 1.23 to 3.12)). The results of CNMA showed that MA was the most effective component (RR = 1.38 (95% CI, 1.12 to 1.70)) when added to usual care.
Conclusion	Acupuncture provided additional benefits to usual care, and it might be considered as adjunctive therapy for patients who respond inadequately to usual care.

1.1.3. Shi 2022 (vs. antispasmodics) ☆☆

Shi YZ, Tao QF, Qin D, Chen M, Yu SG, Zheng H. Acupuncture vs. antispasmodics in the treatment of irritable bowel syndrome: An adjusted indirect treatment comparison meta-analysis. *Front Physiol.* 2022 Oct 6;13:1001978. <https://doi.org/10.3389/fphys.2022.1001978>.

Background	Acupuncture has been extensively applied to manage irritable bowel syndrome (IBS) in clinical practice in China. Some randomized controlled trials (RCTs) have demonstrated their efficacy, but it has rarely been compared with first-line antispasmodics to verify their effectiveness. Therefore, we compare acupuncture with antispasmodics in the treatment of IBS by using an adjusted indirect treatment comparison meta-analysis.
Methods	Embase, OVID Medline, and the Cochrane Central Register of Controlled Trials databases were searched from inception to 14 March 2022, with no language restrictions. RCTs comparing antispasmodics or acupuncture with placebo or one of the antispasmodics were enrolled. The primary outcome of interest was the improvement of abdominal pain. And the secondary outcomes of interest were the relief of global IBS symptoms and adverse events. The random-effects model was utilized to pool data. The effect size was measured by standardized mean difference (SMD) or relative ratio, and the effectiveness of acupuncture and different antispasmodics were ranked by P-scores.

Results	Thirty-five RCTs (n = 5,190) were included. The analysis showed that cimetropium, drotaverine, acupuncture, and pinaverium were superior over placebo in relieving abdominal pain; cimetropium (SMD, -3.00 [95%CI, -4.47 to -1.53], P-score = 0.99) ranked the most effective. In pairwise comparisons, acupuncture had a greater improvement than most antispasmodics except cimetropium and drotaverine in relieving abdominal pain, although the between-group difference was statistically insignificant. In the analysis of continuous outcome in the relief of global IBS symptoms, the result showed that pinaverium was more effective (SMD, 1.72 [95%CI, 0.53 to 2.92], P-score = 0.90) than placebo. Trimebutine and acupuncture had greater improvements than placebo, but no significant difference was shown between groups. In pairwise comparisons, acupuncture was more effective than pinaverium (SMD, -1.11 [95%CI, -1.94 to -0.28]) in relieving global IBS symptoms. In the analysis of adverse events, acupuncture had a lower adverse event rate than most of the other antispasmodics.
Conclusion	Cimetropium, drotaverine, and acupuncture were all better than placebo in improving abdominal pain. Acupuncture was preferred over pinaverium in relieving global IBS symptoms, and acupuncture had lower adverse events than most antispasmodics.

1.1.4. Wei 2022

Wei X, Wen Y, Wei Y, Liang X, Ma X, Zhang B, Tang X. External therapy of traditional Chinese medicine for treating irritable bowel syndrome with diarrhea: A systematic review and meta-analysis. *Front Med (Lausanne)*. 2022 Aug 9;9:940328. <https://doi.org/10.3389/fmed.2022.940328>

Background	Irritable bowel syndrome with diarrhea (IBS-D) is a chronic functional gastrointestinal disorder that has a significant impact on quality of life, work productivity, and healthcare resources. External therapy of traditional Chinese medicine (TCM) has positive effects on IBS-D and is simple, convenient, and low-cost. This study aimed to systematically evaluate the efficacy and safety of external therapy of TCM for IBS-D.
Methods	This study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals (VIP), Wan Fang, and Chinese Biomedical (CBM) databases were electronically searched to collect randomized controlled trials comparing external therapy of TCM with Western medicine for IBS-D from inception to 31 December 2021. Two authors independently screened, extracted, and assessed the selected studies. The Jadad scale and Cochrane Collaboration Risk of Bias tool were used to evaluate study quality. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE). The meta-analysis was performed using the Review Manager software (version 5.3).

Results	Twenty-one studies involving 1,862 subjects were included. Acupuncture and moxibustion were the most commonly used external therapies. The meta-analysis showed that based on total effective rate with moderate certainty of evidence (n = 21 studies, n = 1,862 participants, RR = 1.25, 95% CI [1.2, 1.31], I ² = 0%, P < 0.00001), clinical cure rate with low certainty of evidence (n = 17 studies, n = 1,502 participants, RR = 1.66, 95% CI [1.4, 1.96], I ² = 1%, P < 0.00001), recurrence rate with very low certainty of evidence (n = 5 studies, n = 260 participants, RR = 0.44, 95% CI [0.34, 0.58], I ² = 0%, P < 0.00001), total symptom score (MD = -4.9, 95% CI [-7.34, -2.47]), and IBS severity scoring system score (IBS-SSS) with moderate certainty of evidence (MD = -52.72, 95% CI [-63.9, -41.53]), the experimental group had significant advantages compared with the control group. The sensitivity analysis further confirmed the robustness of the primary outcomes. The improvement in quality of life associated with IBS (IBS-QOL) was superior in the experimental group compared to the control group, and the difference was statistically significant; however, the clinical heterogeneity was strong. The inverted funnel plot of the included studies indicated a potential publication bias.
Conclusion	External therapy of TCM for IBS-D alleviated abdominal symptoms, improved clinical effectiveness, and reduced recurrence with great safety. However, because of the limitations of publication bias in trials, more rigorous studies with a clinical design are necessary for further verification of the outcomes.

1.1.5. Yang 2022

Yang Y, Rao K, Zhan K, Shen M, Zheng H, Qin S, Wu H, Bian Z, Huang S. Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. *Front Public Health*. 2022 Nov 24;10:1022145.

<https://doi.org/10.3389/fpubh.2022.1022145>

Background	Acupuncture and moxibustion have been widely used in the treatment of Irritable Bowel Syndrome (IBS). But the evidence that acupuncture and moxibustion for IBS reduction of symptom severity and abdominal pain, and improvement of quality of life is scarce.
Methods	PubMed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Database, China Biomedical Literature Service System (SinoMed), and unpublished sources were searched from inception until June 30, 2022. The quality of RCTs was assessed with the Cochrane Collaboration risk of bias tool. The strength of the evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation system (GRADE). Trial sequential analysis (TSA) was conducted to determine whether the participants in the included trials had reached optimal information size and whether the cumulative data was adequately powered to evaluate outcomes.

Results	A total of 31 RCTs were included. Acupuncture helped reduce the severity of symptoms more than pharmaceutical drugs (MD, -35.45; 95% CI, -48.21 to -22.68; $I^2 = 71\%$). TSA showed the cumulative Z score crossed O'Brien-Fleming alpha-spending significance boundaries. Acupuncture wasn't associated with symptom severity reduction (SMD, 0.03, 95% CI, -0.25 to 0.31, $I^2 = 46\%$), but exhibited therapeutic benefits on abdominal pain (SMD, -0.24; 95% CI, -0.48 to -0.01; $I^2 = 8\%$) compared to sham acupuncture. Moxibustion show therapeutic benefits compared to sham moxibustion on symptom severity (SMD, -3.46, 95% CI, -5.66 to -1.27, $I^2 = 95\%$) and abdominal pain (SMD, -2.74, 95% CI, -4.81 to -0.67, $I^2 = 96\%$). Acupuncture (SMD, -0.46; 95% CI, -0.68 to -0.24; $I^2 = 47\%$) and the combination of acupuncture and moxibustion (SMD, -2.00; 95% CI, -3.04 to -0.96; $I^2 = 90\%$) showed more benefit for abdominal pain compared to pharmacological medications as well as shams. Acupuncture (MD, 4.56; 95% CI, 1.46-7.67; $I^2 = 79\%$) and moxibustion (MD, 6.97; 95% CI, 5.78-8.16; $I^2 = 21\%$) were more likely to improve quality of life than pharmaceutical drugs.
Conclusion	Acupuncture and/or moxibustion are beneficial for symptom severity, abdominal pain and quality of life in IBS. However, in sham control trials, acupuncture hasn't exhibited robust and stable evidence, and moxibustion's results show great heterogeneity. Hence, more rigorous sham control trials of acupuncture or moxibustion are necessary.

1.1.6. Amsallem 2021 ☆

Amsallem F, Sanchez S, Armoiry X, Mion F. Effectiveness of Non-Pharmacological Interventions for Irritable Bowel Syndrome: A Systematic Review. Evid Based Complement Alternat Med. 2021 Nov 8;2021:4404185. <https://doi.org/10.1155/2021/4404185>

Introduction	Given the complexity of the therapeutic management of irritable bowel syndrome (IBS), alternative non-pharmacological therapies are frequently offered to patients. The aim of this study was to conduct a systematic review in order to establish the current evidence base for non-pharmacological interventions (body-directed and mind-body therapies) in the management of IBS.
Materials and Methods	The literature was searched in several electronic databases (PubMed (including Medline), Web of Science (Clarivate Analytics), Scopus (Elsevier), ScienceDirect (Elsevier), Cochrane Library (Wiley), and Wiley Online Library (Wiley)) for randomized controlled trials (RCTs) published in the English language from 1990 to 2020. Effectiveness outcomes were examined through the change in overall IBS symptoms or abdominal pain up to 12 months after treatment.
Results	11 studies (parallel-group RCTs) were identified that enrolled 1590 participants in total. Body-directed therapies (acupuncture and osteopathic medicine) showed a beneficial effect compared with standard medical treatment for overall IBS symptoms at 6 months follow-up, while no study found any difference between body-directed and sham therapies for abdominal pain or overall IBS symptoms. It was not possible to conclude whether hypnotherapy was superior to standard medical treatment or supportive therapy for overall IBS symptoms or abdominal pain due to discordant results.
Conclusions	Although body-directed therapies such as acupuncture and osteopathic medicine may be beneficial for overall IBS symptoms, higher-quality RCTs are needed to establish the clinical benefit of non-pharmacological interventions for IBS. An important challenge will be the definition of the optimal control groups to be used in non-pharmacological trials.

1.1.7. Wang 2021 ☆

Wang XY, Wang H, Guan YY, Cai RL, Shen GM. Acupuncture for functional gastrointestinal disorders: A systematic review and meta-analysis. *J Gastroenterol Hepatol*. 2021 Nov;36(11):3015-3026.

<https://doi.org/10.1111/jgh.15645>

Objectives	The therapeutic effect of acupuncture treatments (AT) on functional gastrointestinal disorders (FGIDs) is contentious. A meta-analysis was conducted to assess the efficacy and safety of acupuncture for FGIDs.
Methods	The Cochrane Library, EMBASE, PUBMED, Web of Science, Wanfang Database, China National Knowledge Infrastructure, and VIP Database were searched through December 31, 2019 with no language restrictions. Risk ratio (RR) with 95% confidence interval (CI) was calculated to determine the improvement in symptom severity after treatment.
Results	A total of 61 randomized controlled trials (RCTs) on FGIDs were included. The pooled results illustrated the following: compared to pharmacotherapy (RR 1.13, 95% CI 1.09-1.17), placebo acupuncture (RR 1.69, 95% CI 1.37-2.08), no specific treatment (RR 1.86, 95% CI 1.31-2.62), and AT as an adjuvant intervention to other active treatments (RR 1.25, 95% CI 1.21-1.30), AT had more favorable improvements in symptom severity; sub-group analysis results classified according to functional dyspepsia (n=13), irritable bowel syndrome (n=19) , and functional constipation (n=8) also supported this finding; and the incidence of adverse events was lower in AT than in other treatments (RR 0.75, 95% CI 0.56-0.99).
Conclusions	This meta-analysis found that AT was significantly associated with relief of FGIDs symptoms; however, the evidence level was moderate or low. Further data from rigorously designed and well powered RCTs are needed to verify the effectiveness and safety of AT as a FGIDs treatment.

1.1.8. Billing 2020 ☆

Billings W, Mathur K, Craven HJ, Xu H, Shin A. Potential Benefit with Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2020;3565(20):31296-9. [212417]. [doi](#)

Background and aims	Patients with irritable bowel syndrome (IBS) may pursue complementary and alternative medicine (CAM). We conducted a comprehensive systematic review and meta-analysis examining efficacy of CAM vs. placebo or sham in adults with IBS.
Methods	Publication databases were searched for randomized controlled trials of CAM therapies (herbal therapy, dietary supplements, mind-body based, body-based, and energy-healing) in adults with IBS. Data were extracted to obtain pooled estimates of mean improvement in abdominal pain (standardized mean difference [SMD]) and relative risk (RR) of overall response using random effects models. Sensitivity and subgroup analyses along with quality assessments were completed.
Results	Among 2825 articles identified, 66 were included. Herbal therapy (SMD=0.47, 95% CI: 0.20 to 0.75, I ² =82%) demonstrated significant benefit over placebo for abdominal pain (low confidence in estimates). Benefit with mind-body based therapy for abdominal pain was of borderline significance (SMD=0.29, 95% CI: -0.01 to 0.59, I ² =78%). Herbal therapy (RR=1.57, 95% CI: 1.31 to 1.88, I ² =77%), dietary supplements (RR=1.95, 95% CI: 1.02 to 3.73, I ² =75%), and mind-body based therapy (RR=1.67, 95% CI: 1.13 to 2.49, I ² =63%) showed benefit for overall response compared to placebo (low confidence in estimates). Body-based and energy healing therapies [acupuncture included 4RCTs] demonstrated no significant benefit over placebo or sham for abdominal pain or overall response.

Conclusion	CAM therapies such as herbal or dietary supplements and mind-body based approaches may be beneficial for abdominal pain and overall response in IBS. However, overall quality of evidence is low. Rigorous, high quality clinical trials are warranted to investigate CAM in IBS.
-------------------	---

1.1.9. Dai 2020 ☆☆

Dai YK, Wu YB, Li RL, Chen WJ, Tang CZ, Lu LM, Hu L. Efficacy and safety of non-pharmacological interventions for irritable bowel syndrome in adults. World J Gastroenterol. 2020;26(41):6488-6509. [215636]. [doi](#)

Background	Although nonpharmacological interventions (NPI) for irritable bowel syndrome (IBS) have been applied clinically, their relative efficacy and safety are poorly understood. Aim: To compare and rank different NPI in the treatment of IBS.
Methods	Five electronic databases were searched from their inception to January 12, 2020. Data of included publications were analyzed using network meta-analysis (NMA). Quality of endpoints were assessed by tools of the Cochrane Handbook and the GRADEpro software. Pooled relative risk or standardized mean difference with their corresponding 95% confidence intervals were used for statistical analysis. Surface under the cumulative ranking curve (SUCRA) probability value was conducted to rank the examined interventions. Sensitivity analysis was performed to verify the robustness of results and test the source of heterogeneity.
Results	Forty randomized controlled trials with 4196 participants were included in this NMA. Compared with routine pharmacotherapies and placebo, acupuncture and cognitive behavioral therapy (CBT) had better efficacy in relieving IBS symptoms. Based on the SUCRA values, acupuncture ranked first in improving overall clinical efficacy and avoiding adverse effects. CBT ranked first in lowering the scores of IBS symptom severity scale, self-rating anxiety scale and self-rating depression scale.
Conclusion	This study confirmed the efficacy and safety of NPI for improving IBS symptoms, which to some extent recommended several interventions for clinical practice.

1.1.10. Zheng 2019

Zheng H, Chen R, Zhao X, Li G, Liang Y, Zhang H, Chi Z. Comparison between the Effects of Acupuncture Relative to Other Controls on Irritable Bowel Syndrome: A Meta-Analysis. Pain Res Manag. 2019. [203243].

Background	Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder with recurrent abdominal pain and altered defecation habits. We here attempted to determine the effect of acupuncture on IBS.
Methods	Randomized controlled trials (RCTs) published in CNKI, VIP, Wanfang, PubMed, Cochrane Library, EMBASE, Web of science, and ClinicalTrials.gov till July 17, 2019 were searched. Outcomes were total efficacy rates, overall IBS symptom scores, or global quality of life scores. Standardized mean difference (SMD) with 95% confidence intervals (CI) and risk ratio (RR) with 95% CI were calculated for meta-analysis.

Results	We included 41 RCTs involving 3440 participants for analysis. 8 RCTs compared acupuncture with sham acupuncture, among which 3 trials confirmed the biological effects of acupuncture, especially in treating abdominal pain, discomfort, and stool frequency. No significant difference was found when acupuncture was compared with sham acupuncture, in terms of effects on IBS symptoms and quality of life (SMD = 0.18, 95% CI -0.26~0.63, P=0.42; SMD = -0.10, 95% CI -0.31~0.11, P=0.35), but the pooled efficacy rate data showed a better outcome for true acupuncture (RR = 1.22, 95% CI 1.01~1.47, P=0.04), which was not supported by sensitivity analysis. Acupuncture was more effective relative to western medicine in alleviating IBS symptoms (RR = 1.17, 95% CI 1.12~1.23, I ² = 0%, P < 0.00001), whose effect might last 3 months. Besides, acupuncture as an adjunct to western medicine, Chinese medications, or tuina was superior over the single latter treatment (RR = 1.68, 95% CI 1.18 to 2.40, P=0.004; 1.19, 1.03 to 1.36, P=0.02; 1.36, 1.08 to 1.72, P=0.009, respectively), with high heterogeneities.
Conclusions	Relative to sham controls, acupuncture showed no superiority for treating IBS, while the advantage over western medicine was significant. Acupuncture could be used as an adjunct in clinical settings to improve efficacy. Future high-quality and large-sample-size studies with adequate quantity-effect design need to be conducted.

1.1.11. Fu 2018

Fu Chengwei, Jiang Wei. [The Effect of Acupuncture Therapy on Irritable Bowel Syndrome: a meta-analysis]. Asia-Pacific Traditional Medicine. 2018;12:101-105. [201742].

Objective	To systematically compare the effect of acupuncture with pinaverium on irritable bowel syndrome.
Methods	Get together clinical randomized controlled trials of acupuncture therapy for IBS. Database of China Biology Medicine(CBM),China National Knowledge Infrastructure(CNKI),VIP Database, Wanfang data library, and English database PubMed, Cochrane Library, Web of Science. Randomized controlled clinical trials of acupuncture therapy or give priority to acupuncture therapy in the treatment of IBS, bias risk and quality assessment for each inclusion test was conducted by two researchers in accordance with the JADAD score and the Cochrane Handbook 5.1.0 standard, Meta-analysis was performed with Rev.Man 5.3 software.
Results	Eleven studies involving 1685 patients were enrolled, of whom 864 were treated with acupuncture therapy, and 821 patients were treated with pinaverium alone. The result of meta-analysis shows that acupuncture combined with moxibustion was superior to conventional western medicine in the effective RR=1.20,95%CI[1.15~1.25]>1.
Conclusion	Acupuncture therapy is superior to conventional pinaverium in the treatment of IBS.

1.1.12. Chao 2014 ☆☆

Chao GQ, Zhang S. Effectiveness of acupuncture to treat irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2014;20(7):1871-7. [170907]. IF: 2.369

Aim	To evaluate the efficacy of acupuncture for treatment of irritable bowel syndrome (IBS) through meta-analysis of randomized controlled trials.
------------	--

Methods	We searched MEDLINE, PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials from 1966 to February 2013 for double-blind, placebo-controlled trials investigating the efficacy of acupuncture in the management of IBS. Studies were screened for inclusion based on randomization, controls, and measurable outcomes reported. We used the modified Jadad score for assessing the quality of the articles. STATA 11.0 and Revman 5.0 were used for meta-analysis. Publication bias was assessed by Begg's and Egger's tests.
Results	Six randomized, placebo-controlled clinical trials met the criteria and were included in the meta-analysis. The modified Jadad score of the articles was > 3 , and five articles were of high quality. We analyzed the heterogeneity and found that these studies did not cause heterogeneity in our meta-analysis. Begg's test showed $P = 0.707$ and Egger's test showed $P = 0.334$. There was no publication bias in our meta-analysis (Begg's test, $P = 0.707$; Egger's test, $P = 0.334$). From the forest plot, the diamond was on the right side of the vertical line and did not intersect with the line. The pooled relative risk for clinical improvement with acupuncture was 1.75 (95%CI: 1.24-2.46, $P = 0.001$). Using the two different systems of STATA 11.0 and Revman 5.0, we confirmed the significant efficacy of acupuncture for treating IBS.
Conclusion	Acupuncture exhibits clinically and statistically significant control of IBS symptoms.

1.1.13. Pei 2012 ☆☆

Pei LX, Zhang XC, Sun JH, Geng H, Wu XL. [Meta analysis of acupuncture-moxibustion in treatment of irritable bowel syndrome]. Chinese Acupuncture and Moxibustion. 2012;32(10):957-60.[162036]

Purpose	To evaluate the clinical efficacy and safety of acupuncture-moxibustion in treatment of irritable howel syndrome systematically
Methods	Clinical randomized controlled trials on treatment of irritable bowel syndrome with acupuncture□moxibustion were collected. Through retrieval of CNKI□1979 —December of 2011) and VIP (1979—December of 2011), randomized and quasi-randomized controlled clinical trials on treatment of irritable bowel syndrome with control study between acupuncture and sham acupuncture or western medication were included. The test bias risk and quality assessment of each experiment were carried out by two researchers in accordance with the Cochrane Handbook 5.1.0 standard. And RevMan 5.1.6 software was adopted for the Meta analysis.
Results	Eleven researches were included with totally 969 patients. Meta analysis shows that the effective rate of the combined methods of acupuncture and moxibustion [$RR=1.27, 95\% CI(1.09, 1.49)$] is superior to conventional western medication treatment.
Conclusion	Acupuncture-moxibustion for irritable bowel syndrome is better than the conventional western medication treatment.

1.1.14. Manheimer 2012 ☆☆

Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, Berman BM, Lao L.. Acupuncture for Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. AM J Gastroenterol. 2012; 107(6):835-47. [160301].

Objectives	Evidence-based treatment guidelines have been unable to provide evidence-based guidance on the effects of acupuncture for irritable bowel syndrome (IBS) because the only previous systematic review included only small, heterogeneous, and methodologically unsound trials. We conducted a new systematic review and meta-analysis of randomized controlled trials (RCTs) to estimate the effects of acupuncture for treating IBS.
-------------------	--

Methods	MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, Cumulative Index to Nursing and Allied Health, and the Chinese databases Sino-Med, CNKI, and VIP were searched through November 2011. Eligible RCTs compared acupuncture with sham acupuncture, other active treatments, or no (specific) treatment, and evaluated acupuncture as an adjuvant to another treatment. Our outcomes were overall IBS symptom severity and health-related quality of life. Dichotomous data were pooled to provide a relative risk (RR) of substantial improvement after treatment, and continuous data were pooled to provide a standardized mean difference (SMD) in post-treatment scores between groups.
Results	A total of 17 RCTs (N=1,806) were included. We found no evidence of an improvement with acupuncture relative to sham acupuncture on symptom severity (SMD=-0.11, 95% confidence interval (95% CI): -0.35 to 0.13; 4 RCTs) or quality of life (SMD=-0.03, 95% CI: -0.27 to 0.22; 3 RCTs). Because of the homogeneity of the results of the sham-controlled trials, results were unaffected by restriction to the four sham-controlled RCTs that used adequate randomization, blinding, and had few withdrawals/dropouts. Among RCTs that did not use a placebo control, acupuncture was more effective than pharmacological therapy (RR of symptom improvement=1.28, 95% CI: 1.12 to 1.45; 5 RCTs) and no (specific) treatment (RR = 2.11, 95% CI: 1.18 to 3.79; 2 RCTs). There was no difference between acupuncture and Bifidobacterium (RR=1.07, 95% CI: 0.90 to 1.27; 2 RCTs) or between acupuncture and psychotherapy (RR=1.05, 95% CI: 0.87 to 1.26; 1 RCT). Acupuncture as an adjuvant to another Chinese medicine treatment was statistically significantly better than the other treatment alone, in trials with a high risk of bias (RR=1.17, 95% CI: 1.02 to 1.33; 4 RCTs).
Conclusions	Sham-controlled RCTs have found no benefits of acupuncture relative to a credible sham acupuncture control on IBS symptom severity or IBS-related quality of life. In comparative effectiveness Chinese trials, patients reported greater benefits from acupuncture than from pharmacological therapies. Future trials may help clarify whether or not these reportedly greater benefits of acupuncture relative to pharmacological therapies are due entirely to patients' preferences for acupuncture or patients' greater expectations of improvement on acupuncture relative to drugs.

1.1.15. Manheimer 2012 ☆☆

Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L.. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5:CD005111. doi: 10.1002/14651858.CD005111.pub3.[160292]. IF: 6.032.

Purpose	The primary objectives were to assess the efficacy and safety of acupuncture for treating IBS.
Methods	MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, the Cumulative Index to Nursing and Allied Health, and the Chinese databases Sino-Med, CNKI, and VIP were searched through November 2011. Randomized controlled trials (RCTs) that compared acupuncture with sham acupuncture, other active treatments, or no (specific) treatment, and RCTs that evaluated acupuncture as an adjuvant to another treatment, in adults with IBS were included. Two authors independently assessed the risk of bias and extracted data. We extracted data for the outcomes overall IBS symptom severity and health-related quality of life. For dichotomous data (e.g. the IBS Adequate Relief Question), we calculated a pooled relative risk (RR) and 95% confidence interval (CI) for substantial improvement in symptom severity after treatment. For continuous data (e.g. the IBS Severity Scoring System), we calculated the standardized mean difference (SMD) and 95% CI in post-treatment scores between groups.

Results	Seventeen RCTs (1806 participants) were included. Five RCTs compared acupuncture versus sham acupuncture. The risk of bias in these studies was low. We found no evidence of an improvement with acupuncture relative to sham (placebo) acupuncture for symptom severity (SMD -0.11, 95%CI -0.35 to 0.13; 4 RCTs; 281 patients) or quality of life (SMD = -0.03, 95%CI -0.27 to 0.22; 3 RCTs; 253 patients). Sensitivity analyses based on study quality did not change the results. A GRADE analysis indicated that the overall quality of the evidence for the primary outcomes in the sham controlled trials was moderate due to sparse data. The risk of bias in the four Chinese language comparative effectiveness trials that compared acupuncture with drug treatment was high due to lack of blinding. The risk of bias in the other studies that did not use a sham control was high due to lack of blinding or inadequate methods used for randomization and allocation concealment or both. Acupuncture was significantly more effective than pharmacological therapy and no specific treatment. Eighty-four per cent of patients in the acupuncture group had improvement in symptom severity compared to 63% of patients in the pharmacological treatment group (RR 1.28, 95% CI 1.12 to 1.45; 5 studies, 449 patients). A GRADE analysis indicated that the overall quality of the evidence for this outcome was low due to a high risk of bias (no blinding) and sparse data. Sixty-three per cent of patients in the acupuncture group had improvement in symptom severity compared to 34% of patients in the no specific therapy group (RR 2.11, 95% CI 1.18 to 3.79; 2 studies, 181 patients). There was no statistically significant difference between acupuncture and Bifidobacterium (RR 1.07, 95% CI 0.90 to 1.27; 2 studies; 181 patients) or between acupuncture and psychotherapy (RR 1.05, 95% CI 0.87 to 1.26; 1 study; 100 patients). Acupuncture as an adjuvant to another Chinese medicine treatment was significantly better than the other treatment alone. Ninety-three per cent of patients in the adjuvant acupuncture group improved compared to 79% of patients who received Chinese medicine alone (RR 1.17, 95% CI 1.02 to 1.33; 4 studies; 466 patients). There was one adverse event (i.e. acupuncture syncope) associated with acupuncture in the 9 trials that reported this outcome, although relatively small sample sizes limit the usefulness of these safety data.
Conclusion	Sham-controlled RCTs have found no benefits of acupuncture relative to a credible sham acupuncture control for IBS symptom severity or IBS-related quality of life. In comparative effectiveness Chinese trials, patients reported greater benefits from acupuncture than from two antispasmodic drugs (pinaverium bromide and trimebutine maleate), both of which have been shown to provide a modest benefit for IBS. Future trials may help clarify whether or not these reportedly greater benefits of acupuncture relative to pharmacological therapies are due entirely to patients' preferences for acupuncture or greater expectations of improvement on acupuncture relative to drug therapy.

1.1.16. Zhao 2010 ☆☆

Zhao Chen, Mu Jing-Ping, Cui Yun-Hua, Yang Ling, Ma Xiao-Peng, Qi Li. [Meta-analysis on acupuncture and moxibustion for irritable bowel syndrome]. Chinese Archives of Traditional Chinese Medicine. 2010;5:961-963. [186931].

Objectives	To summarize the effectiveness of acupuncture and moxibustion as a therapy for Irritable Bowel Syndrome (IBS).
Methods	RCTs were included, in which trials of acupuncture and moxibustion as a therapy for IBS in recent 10 years were extracted by computer and manual searching, for Meta-analyse. The methodological quality was assessed in accordance with the principles of EBM.

Results	The fixed effect model was to be used and the tests for heterogeneity shows that there were no significant differences ($\chi^2=9.32$, $P=0.41$, $P>0.05$), which means the effectsizes of the trials were homogeneous. We combined and estimated two groups' effectsizes, $RR=1.28$, (95% CI-1.20 to 1.38). Z test showed that the therapeutic effect of two groups were have significant differences ($Z=7.143$, $P<0.00001$), and the rhombus was located at the right side of the medium line.
Conclusions	The therapeutic effect of acupuncture and moxibustion on Irritable Bowel Syndrome is superior to that of western medicine.

1.1.17. Shen 2009 Ø

Shen YH, Nahas R. Complementary and Alternative Medicine for Treatment of Irritable Bowel Syndrome. Can Fam Physician. 2009;55(2):143-8. [153146].

Objectives	To review the evidence supporting selected complementary and alternative medicine approaches used in the treatment of irritable bowel syndrome (IBS).
Methods	QUALITY OF EVIDENCE: MEDLINE (from January 1966), EMBASE (from January 1980), and the Cochrane Database of Systematic Reviews were searched until March 2008, combining the terms irritable bowel syndrome or irritable colon with complementary therapies, alternative medicine, acupuncture , fiber, peppermint oil, herbal, traditional, yoga, massage, meditation, mind, relaxation, probiotic, hypnotherapy, psychotherapy, cognitive therapy, or behavior therapy. Results were screened to include only clinical trials, systematic reviews, and meta-analyses. Level I evidence was available for most interventions.
Results	Soluble fibre improves constipation and global IBS symptoms. Peppermint oil alleviates IBS symptoms, including abdominal pain. Probiotic trials show overall benefit for IBS but there is little evidence supporting the use of any specific strain. Hypnotherapy and cognitive-behavioural therapy are also effective therapeutic options for appropriate patients. Certain herbal formulas are supported by limited evidence, but safety is a potential concern. All interventions are supported by systematic reviews or meta-analyses.
Conclusions	Several complementary and alternative therapies can be recommended as part of an evidence-based approach to the treatment of IBS; these might provide patients with satisfactory relief and improve the therapeutic alliance.
Acupuncture	Acupuncture might be beneficial for some patients with IBS, but current evidence does not support its use.

1.1.18. Lim 2006 ☆

Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD005111. DOI: 10.1002/14651858.CD005111.pub2.[141480]

Purpose	The objective of this systematic review is to determine whether acupuncture is more effective than no treatment, more effective than 'sham' (placebo) acupuncture, and as effective as other interventions used to treat irritable bowel syndrome. Adverse events associated with acupuncture were also assessed.
----------------	---

Methods	The following electronic bibliographic databases were searched irrespective of language, date of publication, and publication status: MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, EMBASE, the Chinese Biomedical Database, the Cumulative Index to Nursing and Allied Health (CINAHL), and the Allied and Complementary Medicine Database (AMED). References in relevant reviews and RCTs were screened by hand. The last date for searching for studies was 7 February 2006. Published reports of randomized controlled trials (RCTs) and quasi-randomised trials of acupuncture therapy for IBS. All eligible records identified were dually evaluated for eligibility and dually abstracted. Methodological quality was assessed using the Jadad scale and the Linde Internal Validity Scale. Data from individual trials were combined for meta-analysis when the interventions were sufficiently similar. Heterogeneity was assessed using the I squared statistic.
Results	Six trials were included. The proportion of responders, as assessed by either the global symptomscore or the patient-determined treatment success rate, did not show a significant difference between the acupuncture and the sham acupuncture group with a pooled relative risk of 1.28 (95% CI 0.83 to 1.98; n=109). Acupuncture treatment was also not significantly more effective than sham acupuncture for overall general well-being, individual symptoms (e.g., abdominal pain, defecation difficulties, diarrhea, and bloating), the number of improved patients assessed by blinded clinician, or the EuroQol score. For two of the studies without a sham control, acupuncture was more effective than control treatment for the improvement of symptoms: acupuncture versus herbal medication with a RR of 1.14 (95% CI 1.00 to 1.31; n=132); acupuncture plus psychotherapy versus psychotherapy alone with a RR of 1.20 (95% CI 1.03 to 1.39; n=100). When the effect of ear acupuncture treatment was compared to an unclearly specified combination of one or more of the drugs diazepam, perphenazine or domperidone, the difference was not statistically significant with a RR of 1.49 (95% CI 0.94 to 2.34; n=48).
Conclusion	Most of the trials included in this review were of poor quality and were heterogeneous in terms of interventions, controls, and outcomes measured. With the exception of one outcome in common between two trials, data were not combined. Therefore, it is still inconclusive whether acupuncture is more effective than sham acupuncture or other interventions for treating IBS.

1.1.19. Hussain 2006 Ø

Hussain Z, Quigley EM. Systematic Review: Complementary and Alternative Medicine in the Irritable Bowel Syndrome. *Aliment Pharmacol Ther.* 2006;23(4):465-71. [141341].

Objectives	Complementary and alternative medical therapies and practices are widely employed in the treatment of the irritable bowel syndrome. AIM: To review the usage of complementary and alternative medicine in the irritable bowel syndrome, and to assess critically the basis and evidence for its use.
Methods	A systematic review of complementary and alternative medical therapies and practices in the irritable bowel syndrome was performed based on literature obtained through a Medline search.
Results	A wide variety of complementary and alternative medical practices and therapies are commonly employed by irritable bowel syndrome patients both in conjunction with and in lieu of conventional therapies. As many of these therapies have not been subjected to controlled clinical trials, some, at least, of their efficacy may reflect the high-placebo response rate that is characteristic of irritable bowel syndrome. Of those that have been subjected to clinical trials most have involved small poor quality studies. There is, however, evidence to support efficacy for hypnotherapy, some forms of herbal therapy and certain probiotics in irritable bowel syndrome.

Conclusions	Doctors caring for irritable bowel syndrome patients need to recognize the near ubiquity of complementary and alternative medical use among this population and the basis for its use. All complementary and alternative medicine is not the same and some, such as hypnotherapy, forms of herbal therapy, specific diets and probiotics, may well have efficacy in irritable bowel syndrome. Above all, we need more science and more controlled studies; the absence of truly randomized placebo-controlled trials for many of these therapies has limited meaningful progress in this area.
Acupuncture	No benefit over sham (1 RCT)

1.2. Special Acupuncture Techniques

1.2.1. Placebo response

1.2.1.1. Wang 2025

Wang Z, Chen Y, Li X, Lin L, Chen B, Chen M, Zheng H. Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis. Qual Life Res. 2025 Jun;34(6):1553-1568. <https://doi.org/10.1007/s11136-025-03927->

Objectives	The impact of placebo response on health outcomes in various diseases, including IBS, is significant. To better understand the effect of different placebo administration methods on the observed outcomes in IBS studies, this meta-analysis aims to explore research findings on the degree of improvement.
Methods	The meta-analysis included 45 randomized, double-blind, placebo-controlled clinical trials involving 5174 patients with confirmed IBS (excluding those with significant comorbidities). The trials were designed to compare the efficacy of different placebo interventions. The primary outcome was the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS), and secondary outcomes included the Irritable Bowel Syndrome Quality of Life Instrument (IBS-QoL) and the IBS Symptom Visual Analog Scale (VAS). An arm-based Bayesian network meta-analysis was performed to examine the relative effectiveness of the placebo interventions on the outcomes.
Results	The analysis revealed that sham moxibustion exhibited the most significant efficacy in reducing IBS-SSS (MD -260.00, 95% CrIs: -288.00 to -232.00). Additionally, sham FMT resulted in significant improvements in IBS-QoL scores (MD 9.23, 95% CrIs - 3.69 to 22.30). Meanwhile, placebo tablet interventions were found to be the most effective in reducing VAS scores (MD 4.71, 95% CrIs, -1.14 to 11.10). Overall, this synthesis provides detailed insights into the effectiveness of placebos in addressing different outcome measures.
Conclusions	Sham moxibustion appears to provide subjective benefits for patients' IBS symptoms. However, the evidence for its efficacy is less robust compared to other interventions, as assessed by GRADE. Understanding the placebo effect in IBS management is crucial for clinical practice and drug development, particularly in placebo comparisons.

1.2.2. Comparison of Acupuncture techniques

1.2.2.1. Zhang 2026

Zhang J, Gao X, Qu Y, Liu J. Comparative efficacy and safety of Chinese medicine external therapies for diarrhea-predominant irritable bowel syndrome: a systematic review and network meta-analysis. Front Med (Lausanne). 2026;13:1867631. <https://doi.org/10.3389/fmed.2026.1867631>

Background	Diarrhea-predominant irritable bowel syndrome (IBS-D) is a chronic functional gastrointestinal disorder that significantly impairs patients' quality of life. While various Chinese medicine external therapies (CMETs) have been widely utilized, their relative superiority and safety remain poorly defined. This study aims to evaluate and rank the comparative efficacy and safety of different CMETs for IBS-D.
Methods	We systematically searched PubMed, Embase, The Cochrane Library, and CNKI from inception to March 2026 for randomized controlled trials (RCTs) evaluating CMETs for IBS-D. The primary outcomes were clinical total effective rate (TER) and the IBS Severity Scoring System (IBS-SSS). Secondary outcomes included IBS-Quality of Life (IBS-QOL), abdominal pain scores, and adverse events (AE). A frequentist network meta-analysis (NMA) was performed using the netmeta package in R software. Interventions were ranked using P-scores. Global and local inconsistency were assessed via Q-statistics and the node-splitting method.
Results	Twenty-two RCTs involving 11 distinct interventions were included. For the clinical total effective rate (TER), moxibustion (P-score = 0.8600) and tuina (P-score = 0.7130) emerged as the top-ranked interventions compared with Western medicine (WM) and placebo. Regarding symptom reduction (IBS-SSS) and abdominal pain relief, electroacupuncture (EA) (P-scores = 0.8854 and 0.8591, respectively) demonstrated superior efficacy over other modalities. Acupoint application combined with WM was found to be the most effective for improving quality of life (P-score = 1.0000). Safety analysis indicated that transcutaneous electrical acustimulation (TEA) (P-score = 0.8108) and placebo had the lowest risk of adverse events. Node-splitting analysis did not indicate statistically significant inconsistency; however, the findings should be interpreted cautiously because formal sensitivity analyses excluding high-risk studies were not feasible for all outcomes.
Conclusion	Chinese medicine external therapies may provide beneficial adjunctive or complementary options for patients with IBS-D. Moxibustion ranked highest for study-defined TER, whereas EA ranked highest for IBS-SSS and abdominal pain reduction. However, CINeMA assessment indicated low or very low confidence in several estimates; therefore, these rankings should be interpreted cautiously.

1.2.2.2. Zhou 2026

Zhou J, Lamichhane N, Guo Y, Huang J, Wang J, Liang J, Zhang X, Zhao M, Xu Z. Effectiveness comparisons of acupoint stimulation therapies for irritable bowel syndrome: A Bayesian network meta-analysis. *Complement Ther Med*. 2026 May;97:103332.

<https://doi.org/10.1016/j.ctim.2026.103332>

Background	Irritable bowel syndrome (IBS) is a chronic functional disorder that significantly impacts patient health, causing physical discomfort and diminished quality of life. We aimed to compare various acupoint stimulation modalities for treating IBS using network meta-analysis (NMA).
Methods	We conducted a systematic search of five electronic databases (PubMed, Cochrane Central Register of Controlled Trials, Embase, Web of Science, and ClinicalTrials.gov) for randomized controlled trials (RCTs) on acupoint stimulation interventions for IBS published from inception to November 8, 2024, without language restrictions. Two authors independently performed data extraction and assessed the risk of bias. Outcomes included symptom severity and quality of life. Bayesian NMA was conducted using STATA 14.0 and Open BUGS 3.2.3.

Results	We identified 12 RCTs that included three different acupoint stimulation interventions (1839 participants)-namely, acupuncture, moxibustion, and placebo. Our NMA results showed that the three acupoint stimulation intervention therapies were effective in reducing symptom severity and improving the quality of life for patients with IBS. The most effective acupoint stimulation intervention was moxibustion, which significantly reduced symptom severity (mean difference [MD] = 101.50; 95 % credible interval [CrI]: 80.36, 122.30) and improved quality of life (MD = -19.75; 95 % CrI: -28.86, -10.75) compared to conventional medication in patients with IBS. Moreover, the adverse events of all interventions were acceptable.
Conclusions	The NMA suggests that moxibustion was the most effective modality in alleviating symptom severity and improving quality of life in patients with IBS, followed by acupuncture.

1.2.3. Acupoint application

1.2.3.1. Wang 2025

Wang Q, Zhao L, Liu J, Chen L, Zhang B, Zhang Q, Lu Y, Gao Y, Zheng X, He Z, Jing S. Meta analysis of clinical efficacy of acupoint application in the treatment of irritable bowel syndrome. *Afr Health Sci*. 2024 Dec;24(4):351-361. <https://doi.org/10.4314/ahs.v24i4.44>

Purpose	The clinical efficacy of acupoint application in the treatment of irritable bowel syndrome (IBS) was evaluated by Meta-analysis.
Method	Computer searched Chinese and English databases for the randomized controlled trials (RCTs) and quasi-randomized controlled trials (CCTs) of TCM external therapy, acupoint application, TCM external application, navel sticking and their combination therapy in the treatment of IBS. The search period is from the establishment of the database to December 2022. The literature was screened independently by 2 researchers according to the standard of nano-ranking, and the data of the other 5 researchers were proofread, screened and extracted. After that, the bias risk of the included study was evaluated, and the data were analysed by RevMan 5.4. software.
Result	(1) A total of 1842 patients, were included in 25 randomized controlled trials , including the acupoint application treatment group (n=928) and conventional therapy control group (n = 914).(2) The quality of the literature method shows that there are 5 high-quality literatures with a score of 4-7, 20 low-quality literatures with a score of 1-3 and few high-quality literatures;(3) In terms of effectiveness, compared with the western medicine control group, the total odds ratio OR [95 % CI] of the total effective rate of the acupoint application treatment group was 4.77 [3.68, 6.20], and the difference was statistically significant (P < 0.05). Shenque, Zhongwan, Pishu and Zusanli are the most commonly used.(4) In terms of literature bias, 2 studies used envelopes to hide, which belonged to “low risk”; 9 studies were blindly implemented and evaluated as “unclear”; and 6 studies were rated as “high risk” because cases fell off but were not reported. The funnel plot shows that the study is scatter symmetrical, the probability of publication bias is small, and the conclusion is reliable.
Conclusion	Acupoint application can improve the effective clinical rate of IBS with fewer adverse reactions, better patient compliance and fewer adverse reactions, but it still needs to be confirmed by high-quality multicenter, large sample randomized controlled trials.

1.2.4. Moxibustion

1.2.4.1. Dai 2022

Dai YQ, Weng H, Wang Q, Guo XJ, Wu Q, Zhou L, Huang L. Moxibustion for diarrhea-predominant irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. *Complement Ther Clin Pract*. 2022 Feb;46:101532. <https://doi.org/10.1016/j.ctcp.2021.101532>

Purpose	Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common functional gastrointestinal disorder that imposes heavy burden on individuals and society. As an external therapy of traditional Chinese medicine (TCM), moxibustion is usually used to treat IBS-D. This study aimed to explore the efficacy of moxibustion in treating patients with IBS-D.
Methods	A systematic search for randomized controlled trials (RCTs) that reported the use of moxibustion in IBS-D treatment was performed in eight databases.
Results	Eleven RCTs including 725 participants meet the inclusion criteria. Compared with other positive treatments (Western medicine, TCM prescription, and acupuncture), moxibustion treatment had superior effects against IBS-D according to the meta-analysis.
Conclusion	This systematic review provided preliminary research evidence that moxibustion is effective in treating IBS-D. Rigorously designed and large-scale RCTs are required to provide more robust evidence in this area.

1.2.4.2. Tang 2016 ☆

Tang B, Zhang J, Yang Z, Lu Y, Xu Q, Chen X, Lin J. Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Evid Based Complement Alternat Med*. 2016. [186285].

Background	The complementary and alternative medicines in treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) are controversial.
Methods	We searched PubMed, Ovid Embase, Web of Science, Cochrane Library databases, CNKI, Wanfang Database, CBM, VIP, and AMED for randomized controlled trials (RCTs) of moxibustion compared with pharmacological medications in patients with IBS-D. A meta-analysis was performed using both fixed and random-effects models based on heterogeneity across studies.
Results	In total, 568 patients in 7 randomized controlled trials were randomly treated with moxibustion and pharmacological medications. The improvement of global IBS-D symptoms and overall scores was significant ($P = 0.0001$ and $P < 0.0001$, resp.) in patients treated by moxibustion only compared to pharmacological medications. The specific IBS-D symptoms of abdominal pain, abdominal distension, abnormal stool, and defecation frequency were alleviated in patients treated by moxibustion compared to pharmacological medications, but no significance was found except for abdominal distension and defecation frequency ($P = 0.03$ and $P = 0.02$, resp.). There were no serious adverse events related to moxibustion.
Conclusions	Moxibustion appears to be effective in treating IBS-D compared with pharmacological medications. However, further large, rigorously designed trials are warranted due to insufficient methodological rigor in the included trials.

1.2.4.3. Park 2013 ☆

Park JW, Lee BH, Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. *BMC Complement Altern Med*. 2013;13:247. doi:

10.1186/1472-6882-13-247. [168397]

Purpose	This systematic review and meta-analysis aimed at critically evaluating the current evidence on moxibustion for improving global symptoms of Irritable bowel syndrome (IBS).
Methods	We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials, AMED, CINAHL, and CNKI databases for randomised controlled trials (RCTs) of moxibustion comparing with sham moxibustion, pharmacological medications, and other active treatments in patients with IBS. Trials should report global symptom improvement as an outcome measure. Risk of bias for each RCT was assessed according to criteria by the Cochrane Collaboration, and the dichotomous data were pooled according to the control intervention to obtain a risk ratio (RR) of global symptom improvement after moxibustion, with 95% confidence intervals (CI).
Results	A total of 20 RCTs were eligible for inclusion (n = 1625) . The risk of bias was generally high. Compared with pharmacological medications, moxibustion significantly alleviated overall IBS symptoms but there was a moderate inconsistency among studies (7 RCTs, RR 1.33, 95% CI [1.15, 1.55], I ² = 46%). Moxibustion combined with acupuncture was more effective than pharmacological therapy but a moderate inconsistency among studies was found (4 RCTs, RR 1.24, 95% CI [1.09, 1.41], I ² = 36%). When moxibustion was added to pharmacological medications or herbal medicine, no additive benefit of moxibustion was shown compared with pharmacological medications or herbal medicine alone. One small sham-controlled trial found no difference between moxibustion and sham control in symptom severity (mean difference 0.35, 95% CI [-0.77, 1.47]). Moxibustion appears to be associated with few adverse events but the evidence is limited due to poor reporting.
Conclusion	This systematic review and meta-analysis suggests that moxibustion may provide benefit to IBS patients although the risk of bias in the included studies is relatively high.

1.2.5. Association with Chinese Herbal Medicine

1.2.5.1. Yan 2019 ★

Yan J, Miao ZW, Lu J, Ge F, Yu LH, Shang WB, Liu LN, Sun ZG. Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2019. [197596].

PURPOSE	To comprehensively evaluate the efficacy and safety of acupuncture combined with Chinese herbal medicine (CHM) in treating irritable bowel syndrome with diarrhea (IBS-D).
METHODS	Relevant randomized controlled trials (RCTs) were systemically retrieved from electronic databases from inception to March 2018, including the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Biological Medical Database (CBM, SinoMed), China Science and Technology Journal Database (VIP), and Wan Fang Data. Meanwhile, pooled estimates, including the 95% confidence interval (CI), were calculated for primary and secondary outcomes of IBS-D patients. Besides, quality of relevant articles was evaluated using the Cochrane Collaboration's risk of bias tool, and the Review Manager 5.3 and Stata12.0 softwares were employed for analyses.

RESULTS	A total of 21 RCTs related to IBS-D were included into this meta-analysis. Specifically, the pooled results indicated that (1) acupuncture combined with CHM might result in more favorable improvements compared with the control group (relative risk [RR] 1.29; 95% CI 1.24-1.35; $P = 0.03$); (2) the combined method could markedly enhance the clinical efficacy in the meantime of remarkably reducing the scores of abdominal pain (standardized mean difference [SMD] -0.45; 95% CI -0.72, -0.17; $P = 0.002$), abdominal distention/discomfort (SMD -0.36; 95% CI -0.71, -0.01; $P = 0.04$), diarrhea (SMD -0.97; 95% CI -1.18, -0.75; $P < 0.00001$), diet condition (SMD -0.73; 95% CI -0.93, -0.52; $P < 0.00001$), physical strength (SMD -1.25; 95% CI -2.32, -0.19; $P = 0.02$), and sleep quality (SMD -1.02; 95% CI -1.26, -0.77; $P < 0.00001$) compared with those in the matched groups treated with western medicine, or western medicine combined with CHM. Additionally, a metaregression analysis was constructed according to the name of prescription, acupuncture type, treatment course and publication year, and subgroup analyses stratified based on the names of prescriptions and acupoints location were also carried out, so as to explore the potential heterogeneities; and (3) IBS-D patients treated with the combined method only developed inconspicuous adverse events; more importantly, the combined treatment had displayed promising long-term efficacy.
CONCLUSIONS	Findings in this study indicate that acupuncture combined with CHM is suggestive of an effective and safe treatment approach for IBS-D patients, which may serve as a promising method to treat IBS-D in practical application. However, more large-scale, multicenter, long-term, and high-quality RCTs are required in the future, given the small size, low quality, and high risk of the studies identified in this meta-analysis.

1.2.6. Liver Dispersing with Spleen Strengthening

1.2.6.1. Li 2016 ☆☆

Li Xiang-li, Liao Jian-qiong, Cai Jing-zhou, Wang Sheng-xu. [Clinically Randomized Control Trials of Liver Dispersing with Spleen Strengthening for Irritable Bowel Syndrome Dominated by Diarrhea: A Meta-analysis]. Journal of Clinical Acupuncture and Moxibustion. 2016;32(4):49-53. [182275].

Objective	The clinically therapeutic effect of liver dispersing with spleen strengthening for irritable bowel syndrome by diarrhea was systematically analyzed to provide reference and assistance for its clinical treatment and research.
Methods	By searching in the Cochrane Library, PubMed, Embase, CNKI, Wangfang, VIP, CBM, clinically randomized controlled trials (RCT) of liver dispersing with spleen strengthening for irritable bowel syndrome by diarrhea published from inception to April 2015 were collected while Revman 5. 2 software was applied to perform the Meta - analysis. Results: Ten studies involving 78 1 participants were included in our Meta - analysis.
Results	The results showed that liver dispersing with spleen strengthening (herbs, Chinese patent drug, acupuncture) had an advantage over western medicine in the treatment of IBS - D [total efficacy: OR = 3. 94, 95 % CI (2. 58 - 6. 0 1), $P < 0. 0 1$], and the symptoms of abdominal pain, abdominal distention and stool consistency were relieved, but the mental symptom was not significantly relieved.
Conclusion	Liver dispersing with spleen strengthening (herbs, Chinese patent drug, acupuncture) is effective for IBS - D patients in relieving clinical symptoms, especially in the symptoms of abdominal pain, abdominal distention and stool consistency. It is safe and there is no serious adverse reaction.

1.3. Special Clinical Forms

1.3.1. Diarrhea-Predominant Irritable Bowel Syndrome

1.3.1.1. Jiang 2022

Retracted: Acupuncture and Moxibustion in the Treatment of Adult Diarrhea Irritable Bowel Syndrome: A Network Meta-analysis. Comput Math Methods Med. 2023 Jul 19;2023:9892851. <https://doi.org/10.1155/2023/9892851>

Jiang X, Guo X, Zhou J, Ye S. Acupuncture and Moxibustion in the Treatment of Adult Diarrhea Irritable Bowel Syndrome: A Network Meta-analysis. Comput Math Methods Med. 2022 Jun 28;2022:9919839. <https://doi.org/10.1155/2022/9919839>

Objective	This study was aimed at comparing the clinical efficacy of acupuncture and moxibustion on irritable bowel syndrome complicated with diarrhea (IBS-D) in adults and providing guidance for clinical treatment.
Methods	PubMed, The Cochrane Library, Embase, CBM, CNKI, and VIP and Wanfang databases were searched to obtain clinical randomized controlled trials (RCTs) on acupuncture and moxibustion in the treatment of IBS-D published from establishment of the database to August 5, 2021. Relevant data were extracted to assess the risk of bias in the included studies, and statistical software Stata 16.0 was used for meta-analysis.
Results	Twenty-one studies were eventually included in the network meta-analysis (NMA), including 1626 patients with IBS-D and 8 therapeutic measures. NMA showed that acupuncture [OR = 0.35, 95%CI (0.25, 0.49), $P < 0.05$], warming needle moxibustion [OR = 6.34, 95%CI (2.83, 14.21), $P < 0.05$], acupuncture+sandwiched moxibustion [OR = 12.83, 95%CI (4.49, 36.64), $P < 0.05$], acupuncture+heat-sensitive moxibustion [OR = 9.86, 95%CI (1.77, 55.00), $P < 0.05$] were more effective than pinaverium bromide in the treatment of IBS-D. Cumulative ranking probability (SUCRA) showed that the comprehensive efficacy of acupuncture and moxibustion (86.8%) and quality of life (QOL) (70.4%) was the best, while the comprehensive efficacy of pinaverium bromide (2.1%) and QOL (16.3%) was the worst. GV20, GV29, ST 25, ST37, ST36, SP6, LR3, and CV12 were used frequently.
Conclusion	Acupuncture+sandwiched moxibustion has the best effect on improving the efficacy and QOL of IBS-D patients. Limited by the number and quality of studies, we still need a large sample, multicenter, and high-quality clinical trials to confirm our findings.

1.3.1.2. Guo 2020 ☆

Guo J, Xing X, Wu J, Zhang H, Yun Y, Qin Z, He Q. Acupuncture for Adults with Diarrhea-Predominant Irritable Bowel Syndrome or Functional Diarrhea: A Systematic Review and Meta-Analysis. Neural Plast. 2020. [215399]. [doi](https://doi.org/10.1155/2020/215399)

Objective	To evaluate the clinical effectiveness and safety of acupuncture therapy in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea (FD) in adults.
Method	Five electronic databases-PubMed, EMBASE, CNKI, VIP, and Wanfang-were searched, respectively, until June 8, 2020. The literature of clinical randomized controlled trials of acupuncture for the treatment of IBS-D or FD in adults were collected. Meta-analysis was conducted by Using Stata 16.0 software, the quality of the included studies was assessed by the RevMan ROB summary and graph, and the results were graded by GRADE.

Result	Thirty-one studies with 3234 patients were included. Most of the studies were evaluated as low risk of bias related to selection bias, attrition bias, and reporting bias. Nevertheless, seven studies showed the high risk of bias due to incomplete outcome data. GRADE's assessments were either moderate certainty or low certainty. Compared with loperamide, acupuncture showed more effectiveness in weekly defecation (SMD = -0.29, 95% CI [-0.49, -0.08]), but no significant improvement in the result of the Bristol stool form (SMD = -0.28, 95% CI [-0.68, 0.12]). In terms of the drop-off rate, although the acupuncture group was higher than the bacillus licheniformis plus beanxit group (RR = 2.57, 95% CI [0.24, 27.65]), loperamide group (RR = 1.11, 95% CI [0.57, 2.15]), and trimebutine maleate group (RR = 1.19, 95% CI [0.31, 4.53]), respectively, it was lower than the dicetel group (RR = 0.83, 95% CI [0.56, 1.23]) and affected the overall trend (RR = 0.93, 95% CI [0.67, 1.29]). Besides, acupuncture produced more significant effect than dicetel related to the total symptom score (SMD = -1.17, 95% CI [-1.42, -0.93]), IBS quality of life (SMD = 2.37, 95% CI [1.94, 2.80]), recurrence rate (RR = 0.43, 95% CI [0.28, 0.66]), and IBS Symptom Severity Scale (SMD = -0.75, 95% CI [-1.04, -0.47]). Compared to dicetel (RR = 1.25, 95% CI [1.18, 1.32]) and trimebutine maleate (RR = 1.35, 95% CI [1.13, 1.61]), acupuncture also showed more effective at total efficiency. The more adverse effect occurred in the acupuncture group when comparing with the dicetel group (RR = 11.86, 95% CI [1.58, 89.07]) and loperamide group (RR = 4.42, 95% CI [0.57, 33.97]), but most of the adverse reactions were mild hypodermic hemorrhage.
Conclusion	Acupuncture treatment can improve the clinical effectiveness of IBS-D or FD, with great safety, but the above conclusions need to be further verified through the higher quality of evidence.

1.3.1.3. Deng 2017 ☆☆

Deng D, Guo K, Tan J1, Huang G, Li S, Jiang Q, Xie J, Xie H, Zhang Z, Chen Y, Peng L. [Acupuncture for diarrhea-predominant irritable bowel syndrome: a meta-analysis]. Zhongguo Zhen Jiu. 2017;37(8):907-912. [43743].

Objective	To systematically evaluate the efficacy and safety of acupuncture on diarrhea-predominant irritable bowel syndrome (IBS) in the past five years.
Methods	Online databases, including CNKI, VIP, WANFANG, PubMed, CBM, ScienceDirect OnSite, Cochrane Library, etc. were searched for randomized controlled trials (RCTs) of acupuncture for diarrhea-predominant IBS. Retrieval time was from January of 2011 to January of 2016. According to modified Jadad standard, the bias risk and quality assessment of each RCT included were evaluated by two researchers. RevMan 5.3 software was adopted for the meta-analysis.
Results	Totally 17 RCTs were included with 1 333 patients . The result of meta-analysis indicated the total effective rate of clinical symptoms improvement in the acupuncture group or acupuncture combined with western medicine group was superior to that in the western medicine group (OR=3.92, 95% CI:2.83~5.43, P<0.01), and the funnel plot was basically symmetry. The result of meta-analysis showed 3-month recurrence rate: OR=0.22, 95% CI:0.12~0.41 (P<0.01), indicating the recurrence rate in the acupuncture group was lower than that in the western medicine group in three months.
Conclusions	Acupuncture for diarrhea-predominant irritable bowel syndrome is superior to conventional treatment of western medication, which can improve the clinical symptoms and reduce the recurrence rate of patients.

1.4. Special outcome

1.4.1. Quality of life

1.4.1.1. Zhou 2025

Zhou J, Lamichhane N, Xu Z, Wang J, Quynh VD, Huang J, Gao F, Zhao M, Chen Z, Zhao T. The effect of acupuncture on quality of life in patients with irritable bowel syndrome: A systematic review and meta-analysis. PLoS One. 2025 Feb 13;20(2):e0314678. <https://doi.org/10.1371/journal.pone.0314678>

Background	Acupuncture has been used to improve the quality of life (QoL) of patients in clinical settings. However, the effect of acupuncture on QoL in patients with irritable bowel syndrome (IBS) remains unclear. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the effect of acupuncture on the QoL of patients with IBS.
Method	PubMed, Cochrane Central Register of Controlled Trials, Embase, and Web of Science were screened from inception to September 2023. RCTs published in English comparing acupuncture with sham acupuncture, usual care, pharmacological interventions, or other therapies were analyzed for QoL in patients with IBS. The primary outcome was QoL and secondary outcomes were the IBS-symptom severity scale (IBS-SSS) and abdominal pain. The Cochrane Collaboration recommendations were used to assess the risk of bias.
Findings	Fourteen articles with 2,038 participants were included. The pooled result showed acupuncture can significantly improve the QoL of patients with IBS compared to the conventional treatment (MD = 6.62, 95% CI, 2.30 to 10.94, $P < 0.001$, $I^2 = 72.45\%$). Additionally, acupuncture was superior to other interventions in relieving the symptoms' severity of IBS (MD = -46.58, 95% CI, -91.49 to -1.68, $P < 0.001$, $I^2 = 90.76\%$). Nevertheless, acupuncture was not associated with abdominal pain reduction (MD = -0.35, 95% CI, -0.91 to 0.20, $P = 0.21$, $I^2 = 0.00\%$). Lower adverse events were observed in the acupuncture group. Thus, the quality of this study was relatively high.
Conclusion	The meta-analysis showed that acupuncture improves QoL and symptom severity in patients with IBS and that the optimal parameters for acupuncture to improve QoL in patients with IBS are 30 minutes of acupuncture per session, less than or equal to five sessions per week, and a 4-week course of treatment. However, more high-quality clinical trials are needed to provide stronger evidence.

1.4.2. Anxiety and depression in irritable bowel syndrome

1.4.2.1. Fang 2025

Fang X, Wang X, Zheng W, Yin Y, Ge X. Effect of Acupuncture on Anxiety, Depression, and Quality of Life in Patients with Irritable Bowel Syndrome: A Meta-Analysis. Int J Behav Med. 2025 Jan 27. <https://doi.org/10.1007/s12529-025-10348-z>

Background	Irritable bowel syndrome (IBS) has been effectively treated with acupuncture, but the significance of quality of life, depression, and anxiety in the assessment of IBS patients has received little consideration. This study examined the impact of acupuncture on depression, anxiety, and quality of life in IBS patients.
-------------------	--

Method	PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), EMBASE, China Science and Technology Journal Database (VIP), Chinese Biological Medical (CBM, SinoMed) Database, and the Wan Fang Database were among the electronic databases from which relevant randomized controlled trials (RCTs) were systematically retrieved between their inception and July 2023. The outcomes included adverse events, total response rate, anxiety, and symptoms of depression, as well as quality of life. In this study, the heterogeneity, publication bias, standardized mean difference (SMD), and risk ratios (RR) with 95% confidence intervals (CI) were estimated.
Results	In this study, 29 RCTs including 3114 participants for analysis (treatment group, 1730; control group, 1384) were included. Compared to other therapies, acupuncture significantly improved the quality of life (SMD = 0.61, 95% CI = [0.26, 0.96], $P < 0.001$) and alleviated anxiety (SMD = - 0.72, 95% CI = [- 1.76, 0.32], $P = 0.18$) and depression (SMD = - 0.74, 95% CI = [- 1.18, - 0.3], $P < 0.001$) in IBS patients. A statistically significant improvement was recorded in their quality of life, and they also displayed fewer symptoms of depression. The total response rate (RR = 1.18, 95% CI = [1.12, 1.25], $P < 0.001$) indicated that acupuncture significantly affected IBS treatment in comparison to other methods. Subgroup analysis of primary outcome indicators revealed that acupuncture demonstrated better results regardless of the duration of intervention and was more effective than Western medicine or sham acupuncture. In addition to the total response rate ($I^2 = 0\%$), the other three outcome indicators showed significant heterogeneity ($I^2 > 50\%$). No publication bias was noted in RR ($P < 0.05$); however, a significant publication bias was observed in quality of life ($P > 0.05$).
Conclusion	Acupuncture can enhance the quality of life and relieve anxiety and depression in patients with IBS with apparent safety; however, a large number of high-quality RCTs are still needed.

1.4.2.2. Hou 2024

Hou Y, Chang X, Liu N, Wang Z, Wang Z, Chen S. Different acupuncture and moxibustion therapies in the treatment of IBS-D with anxiety and depression: A network meta-analysis. *Medicine (Baltimore)*. 2024 Apr 26;103(17):e37982. <https://doi.org/10.1097/MD.00000000000037982>

Background	Currently, a variety of Western medical interventions are available for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) with comorbid anxiety and depression. However, the attendant negative effects also emerge, putting pressure on healthcare resources and socio-economic structures. In recent years, the benefits of acupuncture (ACU) and moxibustion in the treatment of IBS-D with anxiety and depression have gradually emerged. However, there are many types of ACU-moxibustion-related treatments, and the aim of this study is to examine the effectiveness of different ACU-moxibustion therapies in the treatment of anxiety and depression in IBS-D patients.
Methods	Searched and identified randomized controlled trials (RCTs) of ACU for the treatment of anxiety and depression in patients with irritable bowel syndrome (IBS). The search spanned from the establishment of the database until September 1, 2023. Revman 5.4 and Stata 15.0 software were used for network meta-analysis (NMA), and the included interventions were ranked by the area under the cumulative ranking curve.

Results	A total of 26 articles involving 8 interventions were included. In terms of improving HAMA score, MOX was superior to EA, combined therapies, CH, WM and placebo; In terms of improving HAMD score, MOX was superior to ACU, EA, combined therapies, WM and placebo; In terms of improving the SAS score, The combined therapies were superior to EA, CH and WM; In terms of improving SDS scores, The combined therapies were superior to EA, CH and WM; In terms of improving IBS-SSS score, The combined therapies were superior to WM; In terms of reducing recurrence rates, CH was superior to combined therapies; In terms of improving total effective rates, MOX was superior to EA, CH, WM and placebo; MOX, combined therapies, ACU and EA ranked higher in SUCRA of different outcome indicators.
Conclusion	MOX, combined therapies, ACU and EA have certain curative effect on anxiety and depression in patients with IBS-D, and their safety is high. ACU and MOX combined with other therapies also have significant advantages in the treatment effect.

1.4.2.3. Wang 2024

Wang Z, Hou Y, Sun H, Wang Z, Zhang H. Efficacy of acupuncture treatment for diarrhea-predominant irritable bowel syndrome with comorbid anxiety and depression: A meta-analysis and systematic review. *Medicine (Baltimore)*. 2024 Nov 15;103(46):e40207.

<https://doi.org/10.1097/MD.00000000000040207>

Background	Presently, a diverse range of Western medical interventions are accessible for the management of irritable bowel syndrome with diarrhea (IBS-D) concomitant with comorbid anxiety and depression. However, the concomitant adverse effects have also surfaced, exerting strain on healthcare resources and the socio-economic structure. In recent times, the benefits of acupuncture in the management of IBS-D with coexisting anxiety and depression have become progressively evident. Nevertheless, a paucity of evidence-based medicine exists to substantiate the utilization of acupuncture for the treatment of IBS-D with anxiety and depression. The objective of this study is to examine the effectiveness of acupuncture as an intervention for IBS-D with comorbid anxiety and depression.
Methods	We searched 7 databases, including the Chinese Journal Full-text Database, Wanfang Academic Journals Full-text Database, VIP Chinese Scientific Journals Full-text Database, China Biomedical Literature Database, PubMed, Embase, and Cochrane Library, for randomized controlled trials (RCTs) related to acupuncture treatment for IBS with anxiety and depression, published from database inception to August 1, 2023. RevMan 5.4 and Stata 17.0 software were used for meta-analysis of relevant outcome measures.
Results	This study included a total of 16 RCTs, involving 1305 IBS-D patients (691 in the experimental group and 614 in the control group). The meta-analysis results showed that compared to oral medication, acupuncture therapy improved HAMD scores (MD = 0.88, 95% CI = [0.68, 1.07], $P < .00001$), HAMA scores (MD = 2.32, 95% CI = [1.70, 2.93], $P < .00001$), self-rating anxiety scale scores (MD = 11.67, 95% CI = [10.85, 12.49], $P < .00001$), SDS scores (MD = 9.84, 95% CI = [8.52, 11.16], $P < .00001$), IBS-SSS scores (MD = 37.48, 95% CI = [12.17, 62.78], $P = .004$), overall response rate (MD = 1.27, 95% CI = [1.20, 1.35], $P < .00001$), and relapse rate (MD = 0.27, 95% CI = [0.16, 0.47], $P < .00001$) in patients with IBS-D comorbid with anxiety and depression.
Conclusion	Acupuncture treatment has a definite and beneficial effect on IBS-D patients with comorbid anxiety and depression.

1.4.2.4. Wang 2023

Wang X, Shi X, Lv J, Zhang J, Huo Y, Zuo G, Lu G, Liu C, She Y. Acupuncture and related therapies for the anxiety and depression in irritable bowel syndrome with diarrhea (IBS-D): A network meta-

analysis of randomized controlled trials. *Front Psychiatry*. 2022 Dec 23;13:1067329.

<https://doi.org/10.3389/fpsy.2022.1067329>

Objective	A growing number of clinical studies have suggested the value of acupuncture-related therapies for patients with irritable bowel syndrome with diarrhea (IBS-D), and the patient's mental state plays an important role, but there are many types of acupuncture-related therapies involved. This study aimed to evaluate the mental status, efficacy and safety of the different acupuncture-related therapies for IBS-D patients.
Methods	We searched seven databases to collect randomized controlled trials of acupuncture-related therapies for IBS-D. After independent literature screening and data extraction, the quality of the final included literature was evaluated. Hamilton anxiety rating scale (HAMA), hamilton depression rating scale (HAMD), self-rating anxiety scale (SAS), and self-rating depression scale (SDS) was used as the primary outcome indicator. And the network meta-analysis (NMA) was performed by using Revman 5.4, Stata 15.0 and WinBUGS 1.4.3 software, and the surface under the cumulative ranking curve was conducted to rank the included interventions.
Results	We analyzed 24 eligible studies with 1,885 patients , involving eight types of acupuncture and related therapies along with comprehensive therapies. The NMA result shows that: for SAS scores, combined therapies were more efficacious than anti-diarrheal or antispasmodic (western medicine, WM) (SMD: -8.92; 95% CI: -15.30, -2.47); for SDS scores, combined therapies were more efficacious than WM (SMD: -8.45; 95% CI: -15.50, -1.41). For HAMA scores, moxibustion (MOX) was more efficacious than placebo (SMD: -8.66; 95% CI: -16.64, -0.38). For HAMD scores, MOX was more efficacious than all other included interventions. For response rate, MOX was more efficacious than the following interventions: acupuncture (ACU) (SMD:0.29; 95% CI:0.08,0.93), Chinese herb medicine (CH) (SMD:0.09; 95% CI:0.02,0.36), combined therapies (SMD:0.23; 95% CI:0.06, 0.85), electroacupuncture (EA) (SMD:0.06; 95% CI:0.01,0.33), warm acupuncture (WA) (SMD:22.16; 95% CI:3.53,148.10), WM (SMD:15.59; 95% CI:4.68,61.21), and placebo (SMD:9.80; 95% CI:2.90,45.51). Combined therapies were more efficacious than the following interventions: CH (SMD:0.39; 95% CI:0.19,0.80), WA (SMD:4.96; 95% CI:1.30,21.62), and WM (SMD:3.62; 95% CI:2.35,5.66). The comprehensive ranking results show that MOX, ACU, combined therapies, and EA had high SUCRA rankings involving different outcome indicators.
Conclusion	MOX, ACU, combined therapies, and EA better alleviate anxiety and depression among IBS-D patients, and with a higher safety level, may be the optimal therapies. In addition, combining acupuncture-related treatments and other therapies also delivers a higher global benefit level.

1.4.2.5. Li 2022

Li HY, Chen Y, Hu ZY, Chen W, Tang HY, Yu ZY, Ye J. [Meta analysis of acupuncture and moxibustion for anxiety and depression in irritable bowel syndrome]. *Zhen Ci Yan Jiu*. 2022 Sep 25;47(9):821-9. Chinese. <https://doi.org/10.13702/j.1000-0607.20210808>

Objective	To evaluate the effectiveness of acupuncture and moxibustion in the treatment of anxiety and depression in irritable bowel syndrome (IBS) by meta-analysis.
Methods	China National Knowledge Infrastructure (CNKI), Wanfang Data, China Scientific Journal Database (VIP), China Biomedical Literature Service System (SinoMed), PubMed, Embase, and Cochrane Library were searched for randomized controlled trials (RCTs) on acupuncture and moxibustion in the treatment of IBS anxiety and depression from database inception to June 30, 2021. RevMan5.3 and Stata16.0 were used to conduct Meta-analysis of relevant outcome indicators.

Results	A total of 11 RCTs were included in this study, involving 774 IBS patients (431 in the intervention group and 343 in the control group). Eight of them used manual acupuncture (MA) intervention, and the other three used electroacupuncture (EA) intervention. Meta-analysis showed that compared with the western medicine, MA improved the sedation-agitation scale (SAS) scores (MD=5.24, 95%CI=[3.49, 7.00], P<0.000 01) and self-rating depression scale (SDS) scores (MD=8.50, 95%CI=[4.68, 12.32], P<0.000 1) in IBS patients, and there was no significant difference between MA or EA and western medicine in the improvement of Hamilton anxiety rating scale (HAMA) scores (MD=1.10, 95%CI=[0.36, 2.56], P=0.14) and Hamilton depression rating scale (HAMD) scores (MD=0.53, 95%CI=[0.89, 1.94], P=0.47). In terms of total effective rates (RR=1.21, 95%CI=[1.12, 1.31], P<0.000 01) and the irritable bowel syndrome severity scoring system (IBS-SSS) scores (MD=42.16, 95%CI=[27.40, 56.91], P<0.000 01), both MA and EA therapy was superior to western medicine in alleviating gastrointestinal symptoms of IBS patients.
Conclusion	MA and EA can improve the anxiety and depression of IBS patients, while the influence of other acupuncture and moxibustion interventions needs to be deeply explored with more high-quality RCTs.

2. Overviews of Systematic Reviews

2.1. Ma 2024

Ma YY, Hao Z, Chen ZY, Shen YX, Liu HR, Wu HG, Bao CH. Acupuncture and moxibustion for irritable bowel syndrome: An umbrella systematic review. J Integr Med. 2024 Jan;22(1):22-31.
<https://doi.org/10.1016/j.joim.2023.12.001>

Background	Irritable bowel syndrome (IBS) is a functional bowel disease characterized by abdominal pain or discomfort associated with altered bowel habits. Several clinical studies have demonstrated the effectiveness of acupuncture and moxibustion for IBS. Many systematic reviews of acupuncture and moxibustion for IBS have been published in recent years, but their results are not entirely consistent.
Objective	To evaluate the methodological, reporting, and evidence quality of systematic reviews of acupuncture and moxibustion for IBS.
Methods	Search strategy: Systematic reviews of acupuncture and moxibustion for IBS published before February 20, 2023 were searched in eight databases: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data, VIP Database for Chinese Technical Periodicals, and China Biology Medicine. The keywords used for literature search were acupuncture, moxibustion, systematic review, meta-analysis, and irritable bowel syndrome. Inclusion criteria: Systematic reviews and meta-analyses of randomized controlled trials of acupuncture and moxibustion for IBS were included. Data extraction and analysis: Relevant information was independently extracted by two investigators. The A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020), and Grading of Recommendations Assessment, Development and Evaluation (GRADE) were used to evaluate the methodological quality, reporting quality and evidence quality, respectively.

Results	A total of 342 studies were retrieved and 15 systematic reviews were included. The results of AMSTAR 2 showed low methodological quality in 2 studies and very low methodological quality in the remaining 13 studies, with main issues being failure to register a protocol, incomplete search strategy, not providing a list of excluded studies, incomplete consideration of the risk of bias in the included studies, and a failure to assess the publication bias. The results of PRISMA 2020 showed seriously deficient reporting quality of 2 studies, somewhat deficient reporting quality of 12 studies, and relatively complete reporting quality of 1 study, with the main problems being lack of a complete search strategy, non-availability of a list of excluded studies with justification for their exclusion, not conducting heterogeneity and sensitivity analyses, not evaluating the credibility of the evidence, and not registering the protocol. The results of GRADE showed that the quality of the evidence is low or very low.
Conclusion	Most included systematic reviews interpreted findings to suggest that acupuncture and moxibustion have benefits for IBS. However, there is a need to improve the methodological, reporting and evidence quality of the systematic reviews. Larger, multicenter, rigorously designed randomized controlled trials and high-quality systematic reviews are required to obtain more robust evidence.

2.2. Wu 2019 ☆

Wu IXY , Wong CHL , Ho RST , Cheung WKW , Ford AC , Wu JCY , Mak ADP , Cramer H , Chung VCH. Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therap Adv Gastroenterol. 2019. [192630].

Background	An overview of systematic reviews (SRs) and a network meta-analysis (NMA) were conducted to evaluate the comparative effectiveness of acupuncture and related therapies used either alone, or as an add-on to other irritable bowel syndrome (IBS) treatments.
Methods	A total of eight international and Chinese databases were searched for SRs of randomized controlled trials (RCTs). The methodological quality of SRs was appraised using the AMSTAR instrument. From the included SRs, data from RCTs were extracted for the random-effect pairwise meta-analyses. An NMA was used to evaluate the comparative effectiveness of different treatment options. The risk of bias among included RCTs was assessed using the Cochrane risk of bias tool.
Results	From 15 SRs of mediocre quality, 27 eligible RCTs (n = 2141) were included but none performed proper blinding. Results from pairwise meta-analysis showed that both needle acupuncture and electroacupuncture were superior in improving global IBS symptoms when compared with pinaverium bromide. NMA results showed needle acupuncture plus Geshanxiaoyao formula had the highest probability of being the best option for improving global IBS symptoms among 14 included treatment options, but a slight inconsistency exists.
Conclusion	The risk of bias and NMA inconsistency among included trials limited the trustworthiness of the conclusion. Patients who did not respond well to first-line conventional therapies or antidepressants may consider acupuncture as an alternative. Future trials should investigate the potential of (1) acupuncture as an add-on to antidepressants and (2) the combined effect of Chinese herbs and acupuncture, which is the norm of routine Chinese medicine practice.

2.3. Zhang 2014 ☆

Wei Zhang, Jian-Hua Sun, Li-Xia Pei, Xiao-Liang Wu, Jun-Ling Zhou, Lu Chen,. [Traditional chinese medicine for treatment of irritable bowel syndrome: an overview of systematic reviews and metaanalyses]. World Chinese Journal of Digestology. 2014;12:1747-175. [187063].

Objectives	To evaluate the relevant systematic reviews/meta-analyses that focused on the traditional Chinese medicine (TCM) for treatment of irritable bowel syndrome (IBS).
Methods	Databases including Cochrane Library, PubMed, AMED, Embase, CBM, CNKI, VIP and WanFang Data were searched from inception to November 2013 to collect the systematic reviews/meta-analyses that focused on the TCM for IBS. Two reviewers screened the literature according to the inclusion criteria and extracted the data. The AMSTAR was used to evaluate the quality of the included studies, and the GRADE system was used to evaluate the quality of evidence.
Results	A total of 14 relevant systematic reviews/meta-analyses were included, of which 10 evaluated the efficacy of Chinese herbal medicine and 4 evaluated acupuncture and Moxibustion. AMSTAR scores were between 2 and 10 points. The results showed that TCM has advantage over conventional medicine in the treatment of IBS ; however, the evidence quality is low.
Conclusions	This research can provide some references for TCM treatment of IBS. Based on the quality level of GRADE evidence, the evidence user should make an evidence-based decision according to the real condition. TCM clinical research should, based on its own characteristics, select the appropriate research design methods, further develop high-quality clinical studies for the evaluation of Chinese medicine treatment of IBS and provide the high-quality evidence.

3. Methodological quality

3.1. Wang 2026

Wang Y, Zou K, Liu D, Guo Q, Deng Y, Long Y. Reproducibility of Published Meta-Analyses on Acupuncture for Irritable Bowel Syndrome. J Evid Based Med. 2026.

<https://doi.org/10.1111/jebm.70188>

Background	Published meta-analytic results should be reproducible from information available to readers. This study assessed the numerical reproducibility of pairwise meta-analytic estimates of acupuncture for irritable bowel syndrome (IBS).
Methods	Six English- and Chinese-language databases were searched. Eligible systematic reviews reported at least one direct pairwise meta-analysis with recoverable study-level inputs. Each eligible pooled estimate was recomputed. The primary outcome was result-level numerical reproducibility. A prespecified standardized reanalysis was a key secondary analysis. Proportions used review-clustered robust variance estimation.
Results	Twenty-three systematic reviews contributed 176 pooled estimates. Of these, 144 (81.8%, 95% CI 71.4%-92.2%) reproduced exactly, 21 (11.9%, 95% CI 4.2%-19.7%) approximately, and 11 (6.3%, 95% CI 1.4%-11.1%) showed substantive numerical discrepancies. All 11 exceeded the 5% threshold for CI width, whereas 10 retained point estimates within 5% of the published value. No original-method recomputation changed whether the 95% CI excluded the null value. 12 reproduced within one percentage point for 162 estimates (92.0%). The text and forest plot disagreed on the analytic model for 12 of 168 evaluable estimates (7.1%). Under the standardized framework, 26 of 174 estimable results (14.9%; 95% CI 7.5%-22.3%) changed from statistically significant to nonsignificant.
Conclusion	Published pooled estimates were generally reproducible when study-level inputs were recoverable, although uncertainty estimates were more sensitive than point estimates. Complete, internally consistent reporting and availability of data and code would facilitate independent verification.

4. Clinical Practice Guidelines

⊕ positive recommendation (regardless of the level of evidence reported)
 ∅ negative recommendation (or lack of evidence)

4.1. European and North American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN and NASPGHAN) 2025 ∅

Groen J, Gordon M, Chogle A, Benninga M, Borlack R, Borrelli O, Darbari A, Dolinsek J, Khlevner J, Di Lorenzo C, Person H, Sanghavi R, Snyder J, Thapar N, Vlieger A, Sinopoulou V, Tabbers M, Saps M. ESPGHAN/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain-not otherwise specified in children aged 4-18 years. J Pediatr Gastroenterol Nutr. 2025 May 30. <https://doi.org/10.1002/jpn3.70070>

children aged 4-18 years. All of the following therapies were therefore not suggested as treatment options. **Acupuncture...**

4.2. Joint Consensus from the Italian Societies 2023 ∅

Italian Societies of Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP)

Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, Falangone F, Fuccio L, Galeazzi F, Iovino P, Sarnelli G, Savarino EV, Stanghellini V, Staiano A, Stasi C, Tosetti C, Turco R, Ubaldi E, Zagari RM, Zenzeri L, Marasco G. Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). Dig Liver Dis. 2023 Feb;55(2):187-207. <https://doi.org/10.1016/j.dld.2022.11.015>

Statement 2.15: We recommend against the use of complementary alternative therapies, although some reasonably good quality evidence exists for specific approaches [**acupuncture**]

Acupuncture référence : Billings W, Mathur K, Craven HJ, Xu H, Shin A. Potential Benefit With Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:1538-1553.e14

4.3. Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS, Germany) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM, Germany) 2021 ⊕

Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S, Freitag M, Frieling T, Gebhard M, Goebel-Stengel M, Häuser W, Holtmann G, Keller J, Kreis ME, Kruis W, Langhorst J, Jansen PL, Madisch A, Mönnikes H, Müller-Lissner S, Niesler B, Pehl C, Pohl D, Raithel M, Röhrig-Herzog G, Schemann M, Schmiedel S, Schwille-Kiuntke J, Storr M, Preiß JC; Collaborators: Andus T, Buderus S,

Ehlert U, Engel M, Enninger A, Fischbach W, Gillessen A, Gschossmann J, Gundling F, Haag S, Helwig U, Hollerbach S, Karaus M, Katschinski M, Krammer H, Kuhlbusch-Zicklam R, Matthes H, Menge D, Miehlke S, Posovszky MC, Schaefert R, Schmidt-Choudhury A, Schwandner O, Schweinlin A, Seidl H, Stengel A, Tesarz J, van der Voort I, Voderholzer W, von Boyen G, von Schönfeld J, Wedel T. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016. Z Gastroenterol. 2021 Dec;59(12):1323-1415.

<https://doi.org/10.1055/a-1591-4794>

Acupuncture and moxibustion can be used to improve quality of life in patients with IBS.

[Recommendation grade 0, consensus]

Complementary or alternative forms of therapy (acupuncture, TCM, homeopathy, etc.) should not be used in childhood IBS. [Recommendation grade B, consensus]

Acupuncture reference :

641 Manheimer E, Cheng K, Wieland LS. et al Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2012.

642 Chao GQ, Zhang S. Effectiveness of acupuncture to treat irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2014; 20: 1871-1877

643 Park JW, Lee BH, Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complement Altern Med 2013; 13:247

4.4. Japanese Society of Gastroenterology (JSG, Japan) 2020 ☉

The Japanese Society of Gastroenterology. [Evidence-based Clinical Practice Guidelines For Irritable Bowel syndrome, 2020] . 2nd ed. Tokyo: Nankodo Co, Ltd; 2020 [in Japanese] . Cited by Okawa Y, Yamashita H, Masuyama S, Fukazawa Y, Wakayama I. Quality assessment of Japanese clinical practice guidelines including recommendations for acupuncture. Integr Med Res. 2022 Sep;11(3):100838.

<https://doi.org/10.1016/j.imr.2022.100838>

IBS. Weak recommendation (to use)

4.5. Canadian Association of Gastroenterology 2019 ☐

Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG0, Sidani S, Vanner S. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019;2(1):6-29. [197158].

15: We recommend AGAINST offering acupuncture to IBS patients to improve IBS symptoms. GRADE: Strong recommendation, very low-quality evidence.

Acupuncture reference :

- 92. Lim B, Manheimer E, Lao L, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006;(4):CD005111.

- 93. Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2012;(5):CD005111.

4.6. British Society of Gastroenterology 2018 Ø

Lamb CA, Kennedy NA, Raine T, Hendy P, Smith PJ, Limdi JK et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. British Society of Gastroenterology. 2018;:386p. [197080].

Anecdotal evidence supports the use of acupuncture although there are no controlled trials and in this case blinding is an obvious problem.

Acupuncture reference : Manheimer E, Wieland LS, Cheng K, et al. Acupuncture for irritable bowel syndrome: Systematic review and meta-analysis. American Journal of Gastroenterology 2012;107(6):835-47.

4.7. Sociedad Española de Patología Digestiva (SEPD, Espagne) 2016 Ø

Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J. Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332-63. [98987].

No evidence supports recommending acupuncture to improve symptoms or quality of life in patients with IBS-C or FC.

4.8. World Gastroenterology Organisation (WGO) 2015 Ø

Irritable Bowel Syndrome: a Global Perspective World Gastroenterology Organisation. 2015:28p. [196753].

A systematic review of trials of acupuncture was inconclusive due to heterogeneous outcomes. Further research is needed before any recommendations on acupuncture or herbal therapy can be made.

4.9. National Institute for Health and Care Excellence (NICE, UK) 2015 Ø

National Collaborating Centre for Nursing and Supportive Care. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. London (UK): National Institute for Health and Care Excellence (NICE). 2015;37P. [165730].

The use of acupuncture should not be encouraged for the treatment of IBS.[2008]

4.10. American College of Gastroenterology 2009 Ø

Brandt LJ, Chey WD et al, American College of Gastroenterology Task Force on Irritable Bowel Syndrome,. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 suppl 1:S1-S35. [211563]. [doi](#)

Further work is needed before any recommendations on acupuncture or herbal therapy can be made.

4.11. World Gastroenterology Organisation (WGO) 2009 Ø

WGO Global Guideline; Syndrome de l'intestin irritable : Une approche globale World Gastroenterology Organisation Global Guidelines. 2009. 26P. [178703].

Une revue systématique des études sur l'acupuncture s'est révélée peu concluante en raison des résultats hétérogènes. D'autres études sont nécessaires avant que l'on puisse faire des recommandations sur l'acupuncture ou la phytothérapie.

5. Randomized Controlled Trials

5.1. Sources

a = Chao 2014
 b = Park 2013
 c = Pei 2012
 d = Manheimer 2012
 e = Lim 2006

5.2. List

1. An G, Li N, Zhai G, Liu H, Sun J, Liang H, Xu R: Evaluation of the therapeutic effect of acupuncture and moxibustion on irritable bowel syndrome [in Chinese]. Shanghai J Acupunct Moxibustion 2010, 29(6):354-356 [b,d].
2. Anastasi JK, McMahon DJ, Kim GH: Symptom management for irritable bowel syndrome: a pilot randomized controlled trial of acupuncture/moxibustion. Gastroenterol Nurs 2009, 32(4):243-255 [a,b,d].
3. Chen Q: Clinical study on irritable bowel syndrome of diarrhea type with Chang-three-needle technique [in Chinese]. Guangzhou university of Chinese medicine, Guangzhou; 2011.20 [b,d].
4. Chen S, Du D, Ma Y, Xin Q, Gao S, Wang X. Clinical study on herbal cone-partitioned moxibustion for irritable bowel syndrome due to spleen-qi deficiency. Journal of Acupuncture and Tuina Science. 2011;9(5):265-268. [161105].
5. Chen Y, Lai X. [Clinical observation on combined warming needle and patented Chinese medicine for irritable bowel syndrome]. Journal of Acupuncture and Tuina Science. 2009:274-7 [d].
6. Chu H, Huang X, Li X, Cheng H, Ding Y: Moxibustion for diarrhea-type irritable bowel syndrome: a clinical study [in Chinese]. J Anhui Trad ChinMed Coll 2011, 30(6):33-36 [b].
7. Fireman Z, Segal A, Kopelman Y, Sternberg A, Carasso R. Acupuncture treatment for irritable bowel syndrome. A double-blind controlled study. Digestion 2001;64(2):100-3 [e].
8. Forbes A, Jackson S, Walter C, Quraishi S, Jacyna M, Pitcher M. Acupuncture for irritable bowel syndrome: a blinded placebo-controlled trial. World J Gastroenterol 2005; 11: 4040-4044 [a,d,e].
9. Hong ZM, Wang ZL, Chen XJ. [Therapeutic effect of acupoint catgut embedding on irritable bowel syndrome of diarrhea type]. Chinese Acupuncture and Moxibustion. 2011;31(4):311-3. gera[161902].
10. Hu D, Kang M, Xiong J, Deng P: Irritable bowel syndrome with diarrhea (IBS-D) treated with moxibustion on heat-sensitive acupoints: a randomized controlled trial. World J Acupunct-Moxibustion 2012, 22(2):1-5 [b].
11. Huang Z, Jin H: A study on the improved therapeutic effect of colon hydrotherapy combined

- with moxibustion on irritable bowel syndrome [in Chinese]. *Chin J Integr Trad West Med Dig* 2007, 15(5):330-331 [b].
12. Jiang J, Zhao N, Xu J, Wang H: The efficacy observation of trimebutine with ginger partitioned moxibustion for diarrhea-predominant irritable bowel syndrome (IBS-D) [in Chinese]. *Shenzhen J Integr Trad Chin West Med* 2010, 20(4):239-241 [b].
 13. Lembo AJ, Conboy L, Kelley JM, Schnyer RS, McManus CA, Quilty MT, Kerr CE, Drossman D, Jacobson EE, Davis RB. A treatment trial of acupuncture in IBS patients. *Am J Gastroenterol*.2009; 104: 1489-1497 [a,d].
 14. Li H, Peili-Xia, Jzhoujun-Ling, Sun JH . Controlled observation on the efficacy of acupuncture and western medicine on diarrhea-type irritable bowel syndrome. *World Journal of Acupuncture-Moxibustion*. 2013;23(2):11. gera[167166].
 15. Li W. [Treatment of warming needle moxibustion combined with spinal manipulation on irritable bowel syndrome]. *China Practical Medicine*. 2009; 4:212-3 [d].
 16. Liao YC. [Acupuncture treatment for 132 cases of irritable bowel syndrome]. *Clinical Journal of Acupuncture and Moxibustion* 2000;16(6):13-4 [e].
 17. Liu M. [Clinical report of ear acupuncture treatment for functional gastric disorder]. *Shanghai Journal of Acupuncture and Moxibustion* 1995;14(6):247-8 [e].
 18. Liu GZ. [Observation of treatment effect of acupuncture and moxibustion plus psychotherapy for irritable bowel syndrome]. *Zhongguo Zhenjiu* 1997, 17(10):611-612 [b,d,e].
 19. Lowe C, Depew W, Vanner S. A placebo-controlled, doubleblind trial of acupuncture in the treatment of irritable bowel syndrome (IBS). *Gastroenterology* 2000; 118: A3168 [a,d,e].
 20. Luo S, Chen C: Clinical observation of therapeutic effect of thunderbolt moxibustion on constipation-predominant irritable bowel syndrome (IBS-C) [in Chinese]. *Guangxi J Trad Chin Med* 2011, 34(5):268-269 [b].
 21. Luo S, Chen C: Shuxiangjiu (sparse incense moxibustion) for treatment of constipation-predominant irritable bowel syndrome (IBS-C) of stagnation of liver-qi stagnation type patient's curative effect observation [in Chinese]. *Guiding J Trad Chin Med Pharmacy* 2012, 18(1):51-52 [b].
 22. Luo S, Long J, Huang L: The curative effect observation and nursing of moxibustion combined with pinaverium bromide tablets to cure abdominal pain and diarrhea intestine irritable syndrome [in Chinese]. *J Jinggangshan Med Coll* 2008, 15(4):39-40 [b].
 23. Ma YX, Liu X, Liu CZ, Wang L, Guo G, Du D, Wang Z, Ma H, Qi P, Li Z, Guo Y, Yi H, Gao S. Randomized clinical trial: the clinical effects of herb-partitioned moxibustion in patients with diarrhoea-predominant irritable bowel syndrome. *Evid Based Complement Alternat Med*. 2013;2013:605460. doi: 10.1155/2013/605460. gera[166604].
 24. MacPherson H, Tilbrook H, Bland JM, Bloor K, Brabyn S, Cox H, Kang'ombe AR, Man MS, Stuardi T, Torgerson D, Watt I, Whorwell P. Acupuncture for irritable bowel syndrome:primary care based pragmatic randomised controlled trial. *BMC Gastroenterol* 2012; 12: 150 [a].
 25. Ni Y, Lu J: Clinical research on moxibustion treatment of diarrhea type irritable bowel syndrome [in Chinese]. *World J Acupunct-Moxibustion* 2001,11(3):19-23 [b].
 26. Reynolds JA, Bland JM, MacPherson H. Acupuncture for irritable bowel syndrome an exploratory randomised controlled trial. *Acupunct Med*. 2008; 26:8-16. [d].
 27. Rohrböck RB, Hammer J, Vogelsang H, Talley NJ, Hammer HF. Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS. *Am J Gastroenterol* 2004;99:1990-1997. [135539].
 28. Schneider A, Enck P, Streitberger K, et al. Acupuncture treatment in irritable bowel syndrome. *Gut*. 2006; 55:649-54 [d].
 29. Shang Z, Xu M, Tian L: Acupuncture combined with moxibustion in the treatment of 48 patients with diarrhea-predominant irritable bowel syndrome [in Chinese]. *China Med Herald* 2012, 9(3):96-97 [b].
 30. Shi X, Luo J, Tan T. [Clinical observation of electroacupuncture on diarrhea-predominant irritable
-

- bowel syndrome]. *Journal of New Chinese Medicine*. 2010; 42:72-4[d].
31. Sun JH, Wu XL, Xia C, Xu LZ, Pei LX, Li H, Han GY. Clinical evaluation of Soothing Gan and invigorating Pi acupuncture treatment on diarrhea-predominant irritable bowel syndrome. *Chin J Integr Med* 2011; 17: 780-785 [a,d].
 32. Wang J, He D, Kuang Y: Combination of Chinese herbal medicine and moxibustion treatment in 30 cases of diarrhea-predominant irritable bowel syndrome (IBS-D) [in Chinese]. *J New Chin Med* 2009, 41(3):82 [b].
 33. Wang W: Clinical observation of warm needling treatment for diarrheapredominant irritable bowel syndrome (IBS-D) [in Chinese]. *J Emerg Trad Chin Med* 2008, 17(10):1377-1407 [b].
 34. Wu H, Wang J, Chen H, Hua X, Shi Z: The therapeutic effect and immunological mechanism of herbs-partition moxibustion in treating irritable bowel syndrome. *Zhongguo Zhenjiu* 1996, 16(2):43-45 [b].
 35. Xiong X, Lin Y: Acupuncture plus traditional Chinese herbal medicine in treating 42 patients with diarrhea-predominant irritable bowel syndrome (IBS-D) [in Chinese]. *J Fujian Univ Trad ChinMed* 2008, 18(2):38-40 [b,d].
 36. Xue Y, Tian X: A clinical research of the effect of acupuncture and its relationship between free radicals and irritable bowel syndrome [in Chinese]. *Chin Arch Trad Chin Med* 2009, 27(1):111-112 [b,d].
 37. Zeng Y, Bao Y, Chu J, Li H, Zhu G, Zhang W: Effect of moxibustion on diarrhea-dominant irritable bowel syndrome (IBS-D) patients in dog days [in Chinese]. *Chin Arch Trad Chin Med* 2010, 28(8):1774-1776 [b,d].
 38. Zhang Y, Yan C, Xie S: Ginger-partitioned moxibustion at CV8 treatment for 30 cases of diarrhea-predominant irritable bowel syndrome (IBS-D) [in Chinese]. *Jiangxi J Trad Chin Med* 2007, 8:69-70 [b].

From:
<https://www.wiki-mtc.org/> - Encyclopédie des sciences médicales chinoises

Permanent link:
<https://www.wiki-mtc.org/doku.php?id=acupuncture:evaluation:gastro-enterologie:06.%20syndrome%20de%20l%20intestin%20irritable>

Last update: 17 Sep 2026 07:16